PHARMACOLOGY & THERAPEUTICS
COURSE INTRODUCTION

I. Pharmacology and Therapeutics: Course Goals and Objectives

The central goal of the Pharmacology and Therapeutics course is two-fold:

1. To provide students with a solid grounding in the basic concepts and scientific underpinnings of the pharmacological sciences

2. To provide students with a comprehensive introduction to the fundamental Pharmacology and uses of the major classes of clinically important drugs currently used in medical practice.

Specific key concepts and learning objectives will be provided for each individual lecture topic. However, the general course goals are as follows:

At the end of the course the student will be able to:

MEDICAL KNOWLEDGE

1. Explain how the fundamental pharmacological properties of pharmacokinetics and pharmacodynamics influence routes of administration; drug distribution and drug levels in the body; drug efficacy and potency; potential for drug-drug interactions; drug toxicity; and the appropriate choice of drug for pharmacotherapy in a given patient.

2. Explain how to use drug-specific and patient-specific pharmacokinetic parameters to calculate the physiochemical properties that influence rates of drug disposition and clearance in the body, and how these parameters can be used to monitor, design and modify appropriate dosing regimens of drugs in specific patient populations.

3. Describe the process by which new drugs are discovered, developed, tested and finally approved by the Federal Drug Administration for use in the clinic.

4. Discuss the fundamental principles of pharmacogenomics including how specific patient genotypes can influence the pharmacokinetic and pharmacodynamics properties of a drug, thereby affecting the clinical response to particular classes of medications.

5. Describe how pharmacogenomics approaches can be used to influence the drug discovery process and the choice of drugs in the treatment of specific diseases.
6. List the major drugs and drug classes currently used in medical practice and describe their pharmacology including their indications, contraindications, clinical use, mechanisms of action, physiological effects, pharmacokinetic properties, major adverse effects and clinically significant drug interactions.

7. Apply knowledge of the pharmacology of the major drugs and drug classes currently used in medical practice, together with both disease-specific and patient-specific factors to select the most appropriate medication(s) for the effective pharmacotherapy of a given disease or condition in a specific patient.

8. Demonstrate an understanding of the molecular, cellular and physiological mechanisms underlying the pathophysiological changes that occur in the etiology of the most common disease states and describe how targeting these mechanisms with the appropriate choice of drug(s) can act to effectively treat, cure, or mitigate the underlying disease causes and/or symptoms.

9. Discuss the theoretical considerations and principles that underlie the successful pharmacotherapy of the major diseases and conditions.

10. Recognize and explain the rationales behind the use of widely used, national organization-approved treatment algorithms for the management and treatment of common diseases and conditions, including identifying the currently accepted diagnostic criteria required to initiate drug therapy and the anticipated therapeutic goals likely to be achieved by therapeutic intervention.

11. Identify any clinical testing requirements for monitoring the effectiveness and potential toxicity of specific drugs used in the treatment of common diseases and conditions.

12. Explain the physiological, pharmacological, and psychological effects of acute and chronic exposure of individuals to drugs with abuse potential, and the consequences of sudden withdrawal of such a drug from a drug-dependent individual.

13. Describe the effective use of non-pharmacological therapeutic interventions in the treatment of specific diseases, conditions and symptoms.

14. Discuss the basic principles of toxicology; the mechanisms by which excess exposure to certain drugs, toxins, chemicals, heavy metals and poisons can lead to adverse toxicological effects; and the basic principles of clinically managing the poisoned patient.

15. Evaluate the relative advantages and disadvantages in the use of dietary supplements and herbal medications in the treatment of certain specific conditions or diseases, including their efficacy, potential for causing adverse effects and drug interactions.
16. Compare and contrast the major differences in the laws and regulations governing the approval, safety, efficacy and marketing of dietary supplements and herbal medications compared to conventional FDA-approved drugs.

17. Demonstrate an understanding of the design and conduct of basic scientific and clinical research and explain how these findings can be applied to both develop new therapeutic modalities and influence patient care.

INTERPERSONAL AND COMMUNICATION SKILLS

18. Demonstrate the ability to effectively communicate and work collaboratively together with peers in the small group setting to successfully address problems of pharmacological significance.

19. Contribute to the education of peers by actively engaging in small group sessions and other required group work within the course.

PRACTICE-BASED LEARNING AND IMPROVEMENT

20. Critically evaluate one’s performance in the course to identify strengths and personal limitations in either pharmacological knowledge or study methods; develop learning goals to address any deficiencies and actively seek out assistance from appropriate sources to successfully remediate these deficiencies.

21. Demonstrate an ability to use online resources to objectively identify and evaluate the primary basic scientific and clinical literature relevant to pre-clinical drug discovery and drug development.

PROFESSIONALISM

22. Demonstrate professional behavior by completing all course requirements, including course evaluations, in a timely manner.

23. Demonstrate professionalism by behaving in a professional, courteous and respectful manner when engaged in course activities or interacting with course faculty and staff.

24. Demonstrate responsibility and accountability by attending and being punctual at all required course activities such as small groups, team-based learning exercises and exams.
25. Demonstrate professional behavior by requesting any excused absence from required course activities well ahead of the scheduled date.

26. Demonstrate professional behavior by responding to direct communication from the Course Director in a timely fashion, particularly in circumstances when a face-to-face meeting is requested to discuss issues related to academic performance.

27. Demonstrate professional and ethical behavior by honestly completing course examinations without attempting to seek an advantage by unfair means; and by reporting any unethical behavior of peers to the course administration.

II. ORGANIZATION OF THE COURSE.

A. Syllabus
The Pharmacology & Therapeutics course is year-long and is divided into two semesters.

Semester III (Part 1); August 2nd – December 12th, 2016
Semester IV (Part 2); January 5th – April 25th, 2017

You will receive an individual grade for each semester.

Semester III:
There are five major areas of emphasis in Semester III:

(i) Basic Principles — in this series of lectures you will be introduced to the fundamental concepts of Pharmacology including pharmacokinetics, pharmacodynamics, pharmacogenomics, drug metabolism, drug interactions, drug transporters and drug discovery.

(ii) Autonomic Pharmacology/Anesthesia/Pain medications— this section of the course will introduce you to the pharmacology of the autonomic nervous system. You will also be introduced to the pharmacology of anesthetics and analgesics.

(iii) Antimicrobial agents — this section of the semester will provide an introduction to the pharmacology and clinical use of antibiotic drugs used in the treatment of infectious diseases.

(iv) Cardiovascular Pharmacology — in this series of lectures you will be introduced to the major drug classes that are used to treat diseases of the cardiovascular system. These drug classes include those involved in the
regulation of blood coagulation, as well as drugs used to control hyperlipidemia, hypertension, angina, cardiac arrhythmias and congestive heart failure.

**(v) Miscellaneous Pharmacology Topics** - this final section will deal with a number of topics including, pharmacotherapy of anemia, immunomodulation therapy, treatment of allergies and pharmacotherapy of mycobacterial and fungal infections.

There will be a total of **FIVE** exams in Semester III on the following dates:

**August 15th; August 29th; September 16th; October 24th; December 12th.**

*Note: The Pharm course will not have questions on the MHD exam scheduled for November 14th.*

**Semester IV**

There are four major areas of emphasis in Semester IV:

**(i) Psychopharmacology** – the first series of lectures in the semester will provide an introduction to the pharmacology of drugs used in the treatment of common psychiatric illnesses, including the antidepressants, mood stabilizers, anxiolytics, and anti-psychotics. There will also be lectures on sedative hypnotic drugs and drugs used to treat drug abuse.

**(ii) The endocrine system** – this section of the course will discuss the pharmacology of drugs used to treat disorders of the endocrine system. Topics included are hypothalamic and pituitary hormones; estrogens, progesterones and androgens; Adrenocorticosteroids; drugs used to treat thyroid disorders; drugs to treat osteoporosis, and drugs to treat diabetes.

**(iii) Chemotherapy** – the final section of the semester will focus on the pharmacology of drugs used in chemotherapy and the treatment of cancer. Other topics will include drugs to treat HIV and other viral infections, the principles of clinical toxicology, and the pharmacology of common botanical medications and alternative medicine supplements.

**(iv) Other topics** - Other lecture topics that will be introduced throughout the semester include drugs to treat drugs to treat Rheumatoid Arthritis; drugs used in the management of GI disorders; and Herbal Medications and Drug Supplements.

There will be **FOUR** exams in Semester IV on the following dates:
B. Integration with other courses
The Pharmacology and Therapeutics course will run concurrently with Mechanisms of Human Disease. You will find that the lecture topics in these have been integrated so that related topics are coordinated and will be taught in a contemporaneous fashion. This will ensure that you will first hear about the underlying scientific basis of a disease process, its associated pathologies, and symptoms, prior to being introduced to the Pharmacology of the drugs used to treat that specific disease process. The topic areas are further integrated in small group sessions within both the Mechanisms and Pharmacology courses that aim to dovetail knowledge gained from both courses into addressing specific clinical scenarios. It is hoped that by integrating the course material in this way, it will aid the overall educational experience and will greatly facilitate the learning process.

C. Lectures
All Pharmacology lectures will be 50 min in duration and will be presented in SSOM Rm. 390. A PDF printout of the powerpoint presentation of each lecture will be made available for download shortly before each lecture. As always, appropriate and professional behavior in the lecture hall is expected. Distracting classmates and/or faculty with conversation is unprofessional and is not acceptable.

D. Learning objectives and Handouts
A handout that can be used as a study guide for each lecture topic will accompany each lecture and will be posted on the web, where it can be accessed through the calendar for each specific date.

These handouts will include:
   a) A list of suggested reading assignments.
   b) A list of key concepts and learning objectives for each lecture topic.
   c) A list of the important drugs that will be covered during the lecture.
   d) A detailed overview of the material that will be covered in the lecture.
   e) Charts illustrating key Pharmacological features of each drug covered in the lecture, and/or a brief review of key points made in the lecture.
E. **Small Group Case Studies**

In addition to lectures the course also includes a variety of small group case studies. These small group case analyses will typically last 90 min and will take place in assigned locations within the sit-down-labs of SSOM. They will use various clinical case vignettes to illustrate important pharmacological concepts and will attempt to facilitate learning of critical pharmacological information covered in the related lectures. In the first semester the small group cases will be focused on basic pharmacological concepts such as pharmacokinetics, pharmacodynamics drug dosing, drug metabolism, and drug interactions. In the second semester there will be three small group cases that will each focus on the pathophysiology and drug management of an individual psychiatric condition (e.g. bipolar disorder, schizophrenia, depression and drug abuse). The case vignettes and associated study questions will be made available online. Individual small group assignments, room numbers, and the names of the group facilitators will be posted, both on the web and outside Rm. 320. Note that in many cases, Pharmacological topics and the use of drugs in the treatment of specific diseases will be discussed in small group cases delivered within the Mechanisms of Human Disease course.

In addition to the small group cases there will also be two pharmacology demonstrations that will use clinical simulators and standardized patients to illustrate important aspects in the use of autonomic and cardiovascular drugs. These demonstrations will take place at the assigned times in SSOM Rm. 390. You will be expected to have reviewed the cases prior to the class and to come to these sessions ready to fully participate in the discussions.

In line with current school policy attendance at Small Groups is Mandatory- there will be sign up sheets for each separate small group session. Failure to attend and participate in small groups will result in an evaluation of NOT MEETING EXPECTATIONS in your Professional competency component of the course. If, for whatever reason you find that you have a legitimate reason for being unable to attend a particular small group session you should seek advance permission from the Course Director and the Associate Dean for Student Affairs.

III. **BENCH-TO-BEDSIDE PROJECT**

The Bench-to-Bedside project is a small group exercise in which you and your group will engage with the primary biomedical literature in order to both develop important lifelong learning skills and gain an understanding of the ways in which basic and clinical research are performed, evaluated, and explained to patients.
The project is divided into two distinct assignments. For the **first assignment**, you and your group will discuss a recent basic science research paper addressing a significant problem of pharmacological or pathophysiological interest and prepare a group presentation on the topic to be presented to the other three small groups present in your assigned SDL. In addition, you will be required to write a brief report (no more than 400 words) describing the principal findings and clinical significance of the study that could be used to describe the study to a typical patient.

For the **second assignment**, you and your group will be provided with the name of a drug that is either currently undergoing clinical trials, or that has been recently approved. You will then have to work collaboratively together to search the literature in order to identify the relevant papers describing the drugs indications, mechanism of action, relevant pre-clinical data supporting the development of the drug, pharmacokinetic properties, and the details of the clinical trial studies demonstrating safety and efficacy, which you will then need to summarize in the form of a group presentation that will be delivered to the other three small groups in your assigned SDL. You will also be required to write a brief summary (no more than 400 words) of your findings that could be used to explain the clinical use and significance of the drug to a patient.

This project is designed to achieve five major goals: (1) gain an understanding of the ways in which basic and clinical research are performed and evaluated; (2) develop and hone lifelong learning skills including identifying, critiquing and assessing the credibility of relevant biomedical research; (3) working collaboratively and effectively as a team; (4) developing and honing communication and presentation skills; and (5) developing the skills of communicating complex biomedical and clinical concepts to peers, and ultimately patients. **These are all skills and behaviors identified by the medical school accrediting body – the Liaison Committee on Medical Education (LCME)- as being essential for every medical students to develop, and as a result are enshrined within the standards to which every medical school is held accountable.**

**Assignment 1:**
1. Students will be provided with a copy of the relevant biomedical paper for discussion approximately one week prior to the initial small group session.

2. Students should initially read the paper to familiarize them selves with the topic and to identify any areas and concepts that they do not understand that will need to further explored as part of the group.
3. On **August 17th (1:00-3:00pm)** students will meet as part of the first small group session and will discuss the paper amongst themselves, identifying the underlying background and rationale behind the study, the experimental approaches utilized in the study, the principal results of the study and their significance. These small group discussions will be moderated by a faculty facilitator who will help guide the discussion and provide feedback, but is not expected to lecture or provide detailed answers.

4. On **August 24th (10:00 am-12:00pm)** students will meet as part of the second small group session to prepare and present their findings in the form of an informal presentation to the other small groups present in the SDL. These presentations should be in the form of a powerpoint presentation and should involve each member of the group. Each group should be prepared to answer questions from both the faculty and other students.

5. At the completion of the assignment, each student should write a brief report (no more than 400 words) describing the principal findings and clinical significance of the study that could be used to describe the study to a typical patient. These reports should be handed into the Pharmacology and Therapeutics Medical Education Coordinator, Jackie Greer (Rm 320) no later than **Tuesday September 6th**.

**Assignment 2:**

1. At the small group session scheduled for **Monday September 26th (10:30am-12:30pm)** each group will be provided with the name of drug that is either currently undergoing clinical trials, or has recently been approved by the FDA.

2. During the small group session each group should work together to search the biomedical literature in order to identify the relevant papers that help address the following points:

   a) Background on the disease that the drug is intended to treat and the rationale for developing the drug for this indication
   
   b) Description of the drug and its mechanism of action and physiological effects
   
   c) Review of any pre-clinical data supporting the development of the drug (e.g. in vitro and/or animal models)
   
   d) Review of clinical trial data including study design and protocol, results of clinical efficacy data and outcomes, and any significant safety issues.
   
   e) Pharmacological significance and future prospects for patient care
During the small group a faculty facilitator will be present to help guide any discussion, answer any questions and provide feedback, but is not expected to lecture or provide detailed answers on the topic.

3. At the small group on **Thursday September 29**\(^{th}\) (10:30am-12:30pm) students will meet as part of the second small group session to prepare and present their findings in the form of an informal presentation to the other small groups present in the SDL. These presentations should be in the form of a powerpoint presentation and should involve each member of the group. Each group should be prepared to answer questions from both the faculty and other students.

4. At the completion of the assignment, each student should write a brief report (no more than 400 words) to explain the clinical use and significance of the drug to a typical patient who has asked you a question about the drug based on a piece they had read in a newspaper (i.e. what disease the drug is used to treat, how it works, how well does it work, and what, if any are its expected side effects). As part of this report, the student should also include the relevant references (including authors names, title, journal name and page numbers) for the manuscripts describing the drugs mechanism of action and clinical trial results. These reports should be handed into the Pharmacology and Therapeutics Medical Education Coordinator, Jackie Greer (Rm 320) no later than **Monday October 17**\(^{th}\).

**Grading and Assessment**

The combined Bench-to-Bedside project will be worth a total of **4%** of your final course grade for Semester III. The grade will be based upon three independent assessments:

A. Faculty assessment of the quality of the group presentations (40%) - group scores will be applied to each member of the group

B. Assessment of the written reports (40%)

C. Peer-Peer assessment (20%) - based upon the perceived quality of your participation in the group activity as determined by the other members of your group. Each member of the group will have 100 points to distribute amongst the members of the group as they see fit and should be awarded based upon the quality of the participation of each group member in the group activity (students are unable to award points to themselves). Peer-to-Peer evaluation forms will be distributed at a later date and should be returned to Jackie Greer no later than **Monday October 17**\(^{th}\).
Satisfactory completion of the Bench-to-Bedside project will be taken into consideration when completing the outcomes for the Practice-based learning and improvement; Interpersonal and communication skills; and Professionalism competencies. Failure to adequately meet the expectations of any of these competencies will result in a “Does Not Meet” designation and will require subsequent remediation, which, depending on the particular circumstances, could include performing a “make up” assignment and delivering a presentation to the Course Directors.

Attendance and participation in this project is expected. Any unexcused absence will result in the loss of any points associated with the particular assignment and will be appropriately reflected in the competency assessments.

IV. TIPS ON STUDYING FOR PHARM

As indicated above, the first section of semester III will introduce you to the basic scientific principles of Pharmacology. By its very nature this section of the course is very conceptual and deals with very basic fundamental aspects of Pharmacology. However, the remainder of the course will quickly become very specific and is organized in a stepwise fashion to introduce you to the different classes of currently available drugs that are used to treat specific diseases and clinical conditions. This will expose you to a very large amount of information. In order to facilitate your learning and understanding of this material it is helpful to consider the following specific pieces of information for each drug or class of drugs that is covered.

For each drug/drug class you should know the following:

a) INDICATIONS*** - under what circumstances is the drug used.

b) DRUG ACTION*** - what clinical effect does the drug have.

c) MECHANISM OF ACTION*** - how does the drug work at the biochemical level.

d) ADVERSE EFFECTS*** - are there clinically relevant side effects of the drug.

e) CONTRAINDICATIONS*** - are there circumstances in which the drug should not be administered to certain patient populations e.g. the
elderly, those with renal insufficiency, pregnant women etc.

f) PHARMACOKINETICS - are there any factors such as absorption, metabolism, excretion or half-life that might affect the drug action.

g) DRUG INTERACTIONS - are there any interactions with other potentially concomitantly administered drugs that might affect the clinical efficacy, bioavailability or toxicity of either drug.

***- indicates most relevant HIGH YIELD information that is essential to master in order to perform well on the USMLE Step 1 exam.

This information will be discussed for each drug and/or drug class discussed throughout the course. In many cases, the information will be summarized in the charts that will accompany your lecture handouts. By learning this information for each drug/drug class, you will gain a greater appreciation for both the uses and limitations of these drugs in the effective treatment of specific patient populations. Knowing, understanding and being able to apply this information will also be critical for performing well in examinations both in the Pharmacology course and in the USMLE-step 1 exam.

V. EXAM FORMAT & GRADING POLICY.

A. There will be a total of NINE exams throughout the year that contain Pharmacology and Therapeutics questions. All exams will be computerized and will be administered in the Sit-Down Labs.

B. The dates of the exams are:
   Semester III- August 15th; August 29th; September 16th; October 24th; December 12th.

   Note: The Pharm course will not have questions on the MHD exam scheduled for November 14th

   Semester IV- January 20th; March 3rd; April 3rd; April 25th.
C. The total number of questions containing Pharmacology material will vary from exam to exam and will depend on the total number of Pharmacology lectures given during that period of the course.

D. The exams are **NOT** cumulative. Each exam will consist of **three questions per lecture and one questions per small group session that were delivered during the corresponding section of the course**. All questions will all be multi choice format in the style of the United States Medical Licensing Exam (USMLE-Step 1). Total time allowed for each exam will vary depending on the number of exam question- the average time allotted to answer each question will be 1 min 20 sec.

E. Your **final** semester grade will be based on the **total percent correct** of your answers from all of the questions answered in each exam throughout the entire semester.

The final grade for each semester will be compiled as follows:

- **Honors**: a score greater than 90%.
- **High Pass**: a score greater than 80% and less than 90%.
- **Pass**: a score greater than 70% and less than 80%.
- **Fail**: a score less than 70%.

Note: Scores within 0.5 percentage points of a grade cut off will be rounded up to the higher grade

G. In order to pass the entire course you will need to score **AT LEAST** a **PASS** or better in **BOTH** Semester III AND Semester IV.

**VI. PREPARATION FOR EXAMINATIONS.**

A. As part of the handouts for each lecture you should also receive a chart(s) illustrating the major features of the drugs discussed during that lecture (i.e. indications, mechanism of action, adverse effects, contraindications, drug interactions). Alternatively, some lectures may supply you with a list of key review points for the lecture. In either case, these materials should be invaluable resources in your preparations for each exam.

B. USMLE type questions with explanations can be found at the end of each chapter in Katzung and Trevor’s *Examination and Board Review* (9th Edition).
C. An online student Resource Center accompanies the 12th edition of Katzung “Basic & Clinical Pharmacology”. This includes chapter questions and answers with detailed rationales.

D. The following represent Pharmacology-related exam questions that are available online:
URL http://www.medtrng.com/pharmacology_quizzes.htm
URL http://www.med-ed.virginia.edu/courseSites/subjects.cfm?CID=1
URL http://tulane.edu/som/departments/pharmacology/medpharm/quizzes.cfm

VII. MISSED EXAM POLICY.
If circumstances arise that may prevent you from taking a scheduled examination (e.g. serious illness) you should immediately contact BOTH the course directors AND the Associate Dean of Student Affairs, so that a timely adjudication can be made. Students who are forced to miss exams for legitimate reasons, as ascertained by the Associate Dean of Student Affairs, will be given the opportunity to take a make-up exam on an individual basis.

VIII. REMEDIATION POLICY
Students who receive a failing grade for either Semester III or Semester IV will be required to take a Remediation exam. The course director will notify those students that failed a semester after the last exam of that semester. Remediation Exams are administered with the assistance of the Associate Dean of Student Affairs in May/June at the end of the entire course. The purpose of the remediation exam is for the student to demonstrate competence of the material presented in the course. The composition of the exam will be decided by the course director and will consist of representative questions reflecting material that was presented throughout the semester. Students must earn at least a 75% score to pass the remediation exam. The course director will notify the student of the remediation exam grade.

IX. PROFESSIONALISM.
Personal responsibility and professionalism are two key areas in the development of a physician. Professionalism is actually a separate category on the required evaluations for the American College of Graduate Medical Education. It is expected that professionalism will be extended in all aspects of your conduct in this course. This includes appropriate and professional interactions with the course directors, lecturers, educational specialists and other students. Any serious lack in professional conduct will be reported to the Dean.
It is further expected that all students will maintain personal integrity and honesty during the examination process. Once an exam has started there should be no verbal or non-verbal communication with other students. If a problem arises this should be brought to the attention of the examination proctor. Lecture handouts, textbooks, telephones, personal computer devices and any written material should not be taken into the exam room. Neither should these materials be accessed during authorized bathroom breaks. Any student that attempts to gain an unfair advantage over other students in an examination by attempting to gain access to pharmacology resource material by any of these unauthorized means will be guilty of academic misconduct and will be promptly reported to the Dean.

X. TEXTBOOKS

Recommended:


- Available in the Inkling Format for iPad
- Also available through Access Medicine

This is a textbook that is used by many Pharmacology courses at other Medical Schools around the country - it is the companion textbook to the Board Review book listed below. It offers an in-depth detailed discussion of each topic and can be used as a primary resource textbook. It contains excellent summary charts of points at the end of each chapter.

XI. ADDITIONAL TEXTBOOKS AND E-RESOURCES

A. Textbooks.


This voluminous textbook provides a very comprehensive and in depth discussion of all areas of modern clinical pharmacology. It is considered as the “gold standard” of Pharmacology textbooks. However, it would probably be overkill for the course for all but the most interested students.

- available in the Inkling format for iPad
- also available through Access Medicine

This is a condensed readily portable paperback version of the main Goodman & Gilman Reference textbook highlighted above. Highly recommended for those students that want a comprehensive user-friendly Pharmacology resource that can easily be carried in either a pocket or backpack.


6th Edition expected September 22nd 2014

A “user friendly” textbook that provides a basic outline of each topic. Provides just about the right amount of detail for easy review of any given topic. Includes many excellent tables, charts and illustrations for easy review of the material.

B. Review Books


This Board Review book has previously been recommended by past students of the course. It offers a user-friendly brief synopsis of most pharmacological topics with plenty of diagrams, figures and tables. It also includes a list of practice exam questions complete with annotated answers at the end of each section. However, you should be aware that this book provides only a brief review of each topic, not a comprehensive in-depth coverage.


An excellent review book that provides essential facts and information for each of the major drug classes in a succinct user-friendly format- includes many excellent charts and figures. Highly recommended as a board review study aid to complement the lecture handouts provided in the course.

An excellent resource for exam preparation. Essentially Pharm flash cards in a book format. Provides numerous active recall questions on each of the key topics that allows the student to gauge their study progress.

C. **E-Resources**

1. **Scientific American Medicine**
   
   URL [https://www-deckerip-com.archer.luhs.org/decker/scientific-american-medicine/](https://www-deckerip-com.archer.luhs.org/decker/scientific-american-medicine/)

   *This Online Textbook is available through the library e-books collection. It contains a series of excellent up-to-date chapters on a variety of disease process, detailing the underlying biology and pathology of each disease. Most importantly, each chapter ends with a discussion of the available therapeutic approaches to treat each disease, as well as a succinct review of the most important pharmacological aspects of each of the highlighted medications.*

2. **Up-to-Date**
   

   *This website is available through computers on campus and can be accessed via the library web site (under quick links). It provides access to an extensive searchable and clickable database of excellent articles and monographs on specific disease conditions and the medications used to treat them. Provides excellent discussion on all aspects of specific medications including indications, mechanism of action, side effects and drug interactions. An excellent resource of current up-to-date pharmacological information that is widely used on the clinical floors.*

3. **Medical Pharmacology- Online Pharmacology content & Practice questions**
   

   *This is a privately run web site that provides concise review notes on a comprehensive list of Pharmacological topics and specific medications. In addition, it offers the chance to take a number of different online practice exams for each topic. Although I cannot attest to the complete accuracy of the material, it seems that this site would be a good resource for exam preparation.*

4. **The Knowledge Objectives in Medical Pharmacology.**
URL
http://www.aspet.org/AMSPC/Knowledge_Objectives/default.asp

This is the official list of important medications that every US medical student should be familiar with as defined by the Association for Medical School Pharmacology.
X. KEY CONTACTS

COURSE DIRECTOR
Name: Neil A. Clipstone, Ph.D.
Associate Professor of Pharmacology
Associate Dean of Biomedical and Translational Sciences
Location: SSOM Rm 320
Phone/Contacts: Office- x66195
Email – nclipstone@luc.edu

ASSISTANT COURSE DIRECTOR
Name: Debra Hoppensteadt, Ph.D.
Professor of Pathology and Pharmacology
Location: Bldg 102, Room 2643
Phone/Contacts: Office – x64625
Email – dhoppen@luc.edu

MEDICAL EDUCATION COORDINATOR
Name: Jackie Greer
Location: Bldg 120, Room 320
Phone/Contacts: Direct – x68083
Email – jgreer@luc.edu

REMEMBER TO CHECK YOUR E-MAIL ON A REGULAR BASIS. UPDATES AND CHANGES WILL BE ONLY POSTED THROUGH E-MAIL. ALSO CHECK THE WEEKLY COURSE SCHEDULE FOR ANY CHANGES.
### PHARMACOLOGY & THERAPEUTICS FACULTY

**SEMESTER III & IV 2014-2015**

<table>
<thead>
<tr>
<th>Instructor</th>
<th>Department Address</th>
<th>Phone</th>
<th>E-mail address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakowska, Joanna Ph.D.</td>
<td>Pharmacology, Bld 102 Rm 3636</td>
<td>6-8427</td>
<td><a href="mailto:jakow@luc.edu">jakow@luc.edu</a></td>
</tr>
<tr>
<td>Battaglia, George Ph. D.</td>
<td>Pharmacology, Bld. 102, Rm. 3631</td>
<td>6-5608</td>
<td><a href="mailto:gbattag@luc.edu">gbattag@luc.edu</a></td>
</tr>
<tr>
<td>Byram, Scott M.D.</td>
<td>Anesthesia, LUH-Russo Entrance</td>
<td>6-5988</td>
<td><a href="mailto:sbryam@lumc.edu">sbryam@lumc.edu</a></td>
</tr>
<tr>
<td>Byron, Ken, Ph. D.</td>
<td>Pharmacology, Bld. 102, Rm. 2720</td>
<td>7-2819</td>
<td><a href="mailto:kbyron@luc.edu">kbyron@luc.edu</a></td>
</tr>
<tr>
<td>Clipstone, Neil, Ph. D.</td>
<td>SSOM Rm 320</td>
<td>6-6195</td>
<td><a href="mailto:nclipstone@luc.edu">nclipstone@luc.edu</a></td>
</tr>
<tr>
<td>Cuevas, Bruce Ph.D.</td>
<td>Pharmacology, Bld. 102, Rm. 3657</td>
<td>6-6048</td>
<td><a href="mailto:bcuevas@luc.edu">bcuevas@luc.edu</a></td>
</tr>
<tr>
<td>Farreed, Jawed, Ph. D.</td>
<td>Pathology, Bld. 102, Rm. 2652</td>
<td>6-5581</td>
<td><a href="mailto:jfareed@luc.edu">jfareed@luc.edu</a></td>
</tr>
<tr>
<td>Gallagher, Thomas, Ph.D.</td>
<td>Microbiology, Bld. 105, Rm. 3812</td>
<td>6-4850</td>
<td><a href="mailto:tgallag@luc.edu">tgallag@luc.edu</a></td>
</tr>
<tr>
<td>Hoppensteadt, Debra, Ph.D.</td>
<td>Pathology, Bld. 102, Rm 2643</td>
<td>6-4625</td>
<td><a href="mailto:dhoppen@luc.edu">dhoppen@luc.edu</a></td>
</tr>
<tr>
<td>Gentile, Saverio, Ph.D.</td>
<td>Pharmacology, Bld 102</td>
<td>6-3263</td>
<td><a href="mailto:sagentile@luc.edu">sagentile@luc.edu</a></td>
</tr>
<tr>
<td>Grim, Shellee</td>
<td>Medicine- Fahey Bld.</td>
<td>6-6397</td>
<td><a href="mailto:sgrim@lumc.edu">sgrim@lumc.edu</a></td>
</tr>
<tr>
<td>Haske, Michael, M.D.</td>
<td>Anesthesia-LUH-North Entrance</td>
<td>6-6438</td>
<td><a href="mailto:mihaske@lumc.edu">mihaske@lumc.edu</a></td>
</tr>
<tr>
<td>Johnson, Stuart, M.D.</td>
<td>Inf. Disease, Bld. 54, Rm. 149</td>
<td>6-3232</td>
<td><a href="mailto:sjohnson@lumc.edu">sjohnson@lumc.edu</a></td>
</tr>
<tr>
<td>Kennedy, Richard, Ph. D.</td>
<td>Research Svs., Bld. 120, Rm. 411</td>
<td>6-8434</td>
<td><a href="mailto:rkennedy@luc.edu">rkennedy@luc.edu</a></td>
</tr>
<tr>
<td>Kini, Ameet, M.D.</td>
<td>Pathology, Bld. 110, Rm. 2220</td>
<td>7-2611</td>
<td><a href="mailto:akini@lumc.edu">akini@lumc.edu</a></td>
</tr>
<tr>
<td>Kristopaitis, Theresa, M.D.</td>
<td>Medicine, Bld. 54, Rm. 109</td>
<td>6-8757</td>
<td><a href="mailto:tkristo@lumc.edu">tkristo@lumc.edu</a></td>
</tr>
<tr>
<td>Labuszewski, Laurie</td>
<td>Infectious Disease – Fahey Bld</td>
<td>6-2307</td>
<td><a href="mailto:llabruszewski@lumc.edu">llabruszewski@lumc.edu</a></td>
</tr>
<tr>
<td>Marchese, Adriano, Ph. D.</td>
<td>Pharmacology, Bld. 102, Rm. 2720</td>
<td>6-3456</td>
<td><a href="mailto:amarchese@lumc.edu">amarchese@lumc.edu</a></td>
</tr>
<tr>
<td>Majetschak, Matthias, M.D., Ph.D.</td>
<td>BSTI, EMS 110</td>
<td>7-2472</td>
<td><a href="mailto:mmajetschak@luc.edu">mmajetschak@luc.edu</a></td>
</tr>
<tr>
<td>Micetich, Kenneth, M.D.</td>
<td>Hematology/Oncology, Bld. 112,</td>
<td>7-3144</td>
<td><a href="mailto:kmicit@lumc.edu">kmicit@lumc.edu</a></td>
</tr>
<tr>
<td>Michelfelder, Aaron</td>
<td>Family Medicine- Fahey Bld</td>
<td>6-1116</td>
<td><a href="mailto:amichelf@lumc.edu">amichelf@lumc.edu</a></td>
</tr>
<tr>
<td>O’Keefe, Paul M.D.</td>
<td>Medicine – LUH – North Entrance</td>
<td>6-3232</td>
<td><a href="mailto:pokeefe@lumc.edu">pokeefe@lumc.edu</a></td>
</tr>
<tr>
<td>Quinn, Andrea, Pharm. D.</td>
<td>Pharmacy – LUH – Russo Entrance</td>
<td>6-9545</td>
<td><a href="mailto:aquinn@lumc.edu">aquinn@lumc.edu</a></td>
</tr>
<tr>
<td>Reid, Gail</td>
<td>Medicine – Fahey building</td>
<td>6-6393</td>
<td><a href="mailto:greid@lumc.edu">greid@lumc.edu</a></td>
</tr>
<tr>
<td>Robinson, John, M.D.</td>
<td>Rheumatology, Bld. 54, Rm. 113</td>
<td>6-5139</td>
<td><a href="mailto:jrobins@lumc.edu">jrobins@lumc.edu</a></td>
</tr>
<tr>
<td>Samarel, Allen, M.D.</td>
<td>Cardiovasc, Research Bld. 110,</td>
<td>7-2821</td>
<td><a href="mailto:asamare@luc.edu">asamare@luc.edu</a></td>
</tr>
<tr>
<td>Crawford Tonya</td>
<td>Infectious Disease – Fahey Bld</td>
<td>6-5026</td>
<td><a href="mailto:tscardina@lumc.edu">tscardina@lumc.edu</a></td>
</tr>
<tr>
<td>Schilling, David, M.D.</td>
<td>Psychiatry, Bld. 105, Rm. 1940</td>
<td>6-5073</td>
<td><a href="mailto:dschill1@lumc.edu">dschill1@lumc.edu</a></td>
</tr>
<tr>
<td>Scrogin, Karie, Ph. D.</td>
<td>Pharmacology, Bld. 102,</td>
<td>6-5652</td>
<td><a href="mailto:kscrogi@lumc.edu">kscrogi@lumc.edu</a></td>
</tr>
</tbody>
</table>

Jackie Greer  
Medical Education Specialist  
Bld. 120, Rm  
6-8083  
jgreer@lumc.edu
PRINCIPLES OF PHARMACOLOGY: AN OVERVIEW

Date: August 2, 2016 – 8:30 am

KEY CONCEPTS AND LEARNING OBJECTIVES

1. Identify some of the major drug categories for the treatment of various diseases.
2. Discuss the chemical nature of drugs with reference to their origin.
3. List the different origins and sources of drugs and the different types of drug formulations.
4. Describe the various routes of administration of drugs.
5. List the various factors that affect drug absorption, drug distribution and drug excretion.
6. Describe Fick’s law of diffusion.
7. Distinguish the major difference between First Order elimination and Zero Order elimination.
8. Distinguish between a multicomponent distribution model and a single compartment distribution model.
9. Define receptors and their role in the mediation of drug response and differentiate between a receptor agonist and antagonist.
10. Discuss the differences between generic versions of a drug versus the branded product.
11. Define the bioavailability of a drug.
12. Identify the main phases and purposes of the drug approval process.
PRINCIPLES OF PHARMACOLOGY: An Overview

A. WHAT IS PHARMACOLOGY?

Pharmacology represents an integrated body of knowledge that deals with the actions of chemical and biologics on cellular functions.

1. Medical Pharmacology is the area of pharmacology that covers the use of drugs in the prevention (prophylaxis) and treatment of diseases.

2. Toxicology is the area of pharmacology concerned with the undesirable effects of chemicals and biologicals on cellular functions.

3. Pharmacokinetics describes the effects of the body on drugs (absorption, distribution, excretion) and pharmacodynamics describes the action of drugs on the body such as the mechanism of action and therapeutic and toxic effects.

4. Pharmacology is the most integrated multidisciplinary science. It requires knowledge of all of the basic and clinical sciences to understand the mechanism of action of drugs.

B. MAJOR DRUG CLASSES FOR THE TREATMENT OF VARIOUS DISEASES

1. Autonomic drugs- These drugs target the involuntary, unconscious portion of the nervous system.
   a. Cholinoceptor-activating and cholinesterase-inhibiting drugs
   b. Cholinoceptor blockers and cholinesterase regenerators
   c. Sympathomimetics
   d. Adrenoreceptor blockers

2. Cardiovascular drugs
   a. Antihypertensive agents
   b. Drugs used in the treatment of acute coronary syndrome (ACS)
   c. Drugs used in the treatment of heart failure
   d. Anti-arrhythmic drugs
   e. Diuretic agents

3. Drugs effecting smooth muscle cells
   a. Histamine, serotonin and ergot alkaloids
b. Vasoactive peptides
c. Prostaglandins and their modulators
d. Nitric oxide donors and inhibitors
e. Bronchodilators

4. **Drugs that act on the central nervous system**
   a. Sedative/hypnotic drugs
   b. Alcohols
c. Anti-seizure drugs
d. General and local anesthetics
e. Skeletal muscle relaxants
f. Anti-Parkinsonian drugs
g. Anti-psychotic drugs
h. Anti-depressant drugs
i. Opioids analgesics and antagonists
j. Drugs of abuse

5. **Drugs with actions on blood, inflammation and gout**
   a. Anti-anemia drugs and hematopoietic growth factors
   b. Drugs used in the management of thrombosis
c. Anti-hyperlipidemic agents
d. Non-steroidal anti-inflammatory agents

6. **Endocrine drugs**
   a. Hypothalamic and pituitary hormones
   b. Thyroid and anti-thyroid drugs
c. Corticosteroids and antagonists
d. Gonadal hormones and inhibitors
e. Pancreatic hormones, anti-diabetics and hyperglycemic drugs
f. Drugs that affect bone mineral homeostasis

7. Chemotherapeutic agents
   a. Antibiotics
   b. Anti-fungal agents
   c. Anti-viral chemotherapy
   d. Anti-protozoal drugs
   e. Anti-helmentic drugs
   f. Cancer chemotherapy
   g. Immuno-modulators

8. Drugs used in the treatment of gastrointestinal disorders
   a. Drugs used in acid-peptic diseases
   b. Drugs stimulating GI motility
   c. Laxatives
   d. Anti-diarrheal agents
   e. Anti-emetics

9. Vaccines, complex biologic drugs and immune globulins
   a. Active immunization-goal is 1st immune response with memory
   b. Passive immunization- goal is short-term protection in specific populations

10. Stem cell therapy
    a. Stem cell therapy is the use of stem cells to treat or prevent a disease or condition
    b. Stem cell therapy to treat various diseases, such as cancer, diabetes and neurodegenerative disorders are being clinically tested.

11. Monoclonal antibodies

C. THE NATURE OF DRUGS
    1. Inorganic ions
    2. Non-peptide organic molecules and organomimetics
3. Small peptides and peptidomimetics
4. Natural and recombinant proteins
5. Nucleic acids and their analogues
6. Lipids and lipid derived agents
7. Carbohydrates and their derivatives

The molecular weight of drugs varies from 7 daltons (Li⁺) to > 100,000 daltons (antibodies, vaccines, enzymes)

D. ORIGIN AND SOURCE OF DRUGS
1. Microbes
2. Plants
3. Animals
4. Inorganic elements and compounds
5. Synthetic organic compounds
6. Synthetic organomimetics
7. Biotechnology derived products
8. Biologics and products of human origin/recombinant equivalents

E. DRUG FORMULATIONS
1. Liquid
2. Tablets
3. Suppositories
4. Sprays and inhalants
5. Ointments
6. Transdermal patches
7. Drug coating on medical devices (stents, catheters, extracorporeal circuits)
8. Drug implants
9. Micro and nanoparticles
10. Targeted drug delivery

F. ABSORPTION OF DRUGS

1. Route of absorption
   a. Intravenous
   b. Intramuscular
   c. Subcutaneous
   d. Buccal and sublingual
   e. Rectal
   f. Inhalation
   g. Transdermal
   h. Other

2. Blood flow
3. Concentration

G. MOVEMENT (TRANSPORTATION) OF DRUGS IN THE BODY

4. Permeation
   a. Aqueous diffusion
   b. Lipid diffusion
   c. Transport by special carriers
   d. Endocytosis

5. Fick’s law of diffusion
   a. Predicts the rate of movement of molecules across a barrier.
   b. The concentration gradient \((C_1 - C_2)\) and permeability coefficient for the drug and the thickness of the barrier impact drug diffusion.

\[
\text{Rate} = (C_1 - C_2) \times \frac{\text{Permeability coefficient}}{\text{Thickness}} \times \text{Area}
\]

H. AQUEOUS AND LIPID SOLUTION OF DRUGS

1. Aqueous diffusion
2. Lipid diffusion
   The pH of the medium determines the fraction of drug which is charged (ionized) versus uncharged (non-ionized). If the pK\(_a\) of the drug and pH on the medium are known, the amount of ionized drug can be predicted by means of Henderson-Hasselbalch equation.

3. Ionization of weak acids and bases
   \[
   \text{RNH}_3^+ \leftrightarrow \text{RNH}_2 + \text{H}^+
   \]
RCOOH$^+$ $\leftrightarrow$ RCOO$^-$ + H$^+$

I. DISTRIBUTION OF DRUGS

1. Determinants of distribution
   a. Size of the target site (organ)
   b. Blood flow
   c. Solubility
   d. Binding

2. Apparent volume of distribution and physical volume

J. METABOLISM OF DRUGS

1. Drug metabolism as a mechanism of termination of drug action

2. Drug metabolism as a mechanism of drug activation

3. Drug elimination without metabolism

K. ELIMINATION OF DRUGS

1. First order elimination

First order elimination implies that the rate of elimination is proportional to the concentration.

The higher the concentration of drug the greater amount of drug is eliminated per unit time.
1. First-order elimination

First-order elimination implies that the rate of elimination is proportional to the circulating levels of the drug. (more common)

Figure 1. First-order kinetics of drug elimination. The rate of elimination is proportional to the circulating levels of the drug.

2. Zero order elimination

Zero order elimination implies that the rate of elimination is constant regardless of the concentration.
Figure 2. Zero-order kinetics of drug elimination. The rate of elimination is constant and independent of circulating levels of the drug. (less common)

L. **PHARMACOKINETIC MODELS**

1. Multicomponent distribution

Many drugs undergo an initial distribution phase followed by a slow elimination phase. Mathematically this process can be modeled by means of a two compartment model.
2. Single compartment distribution

A few drugs may behave as they are distributed to only one compartment (vascular compartment). Others have more complex distributions that require more than two compartments for construction of accurate models.

M. RECEPTORS FOR DRUGS

Drug effects result from their interactions with endogenous macromolecules in the patients that are called receptors. Upon interaction with the receptor, a drug can initiate biophysical and biochemical events leading to the observed drug effects. Drugs can bind to receptors with a variety of different bonds, which include covalent, electrostatic, and weaker bonds (hydrophobic, Van der Waals and hydrophilic).

1. Types of receptors
   a. Type I receptors: plasma membrane
      - Acetylcholine and norepinephrine
   a. Type II receptors: cytoplasm
      - Steroid hormones
   c. Type III receptors: nucleus
      - Anticancer drugs

2. Agonists: is a drug capable of fully activating the effector system when it binds to the receptor.
3. Antagonists: structural similarity to agonist and interact with receptor but does not cause same molecular change in receptor, therefore inhibits interaction of agonist with receptor.

4. Chain of events following a drug – receptor interaction

\[ \text{Ach} + \text{receptor} \rightarrow \text{Na}^+ \text{ influx} \rightarrow \text{action potential} \rightarrow \text{increased free Ca}^{2+} \rightarrow \text{contraction} \]

- Depends on particular receptor and particular type of cell.

5. Exceptions to drug actions mediated by specific receptors
a. Volatile anesthetics
b. Metal chelating agents
c. Osmotic diuretics

6. Regulation of receptors
a. Down-regulation (pharmacodynamic tolerance or desensitization): repeated administration of catecholamines decreasing number of alpha-receptors.
b. Up-regulation (pharmacodynamic sensitization): thyroid hormone increasing number of beta-receptors in myocardium.

7. Receptor Changes In Diseases
a. Antibodies to acetylcholine receptors in motor end-plates.
   Clinical application: Myasthenia gravis.
b. Decreased number of receptors for plasma LDL (low density lipoproteins)
   Clinical application: Familial hypercholesterolemia.

N. **DRUG ANTAGONISMS**

1. Competitive antagonism: reversible competition for agonist receptor binding sites without inducing a biological response, such as: Naloxone to reverse opioid overdose and flumazenil which is an antidote to benzodiazepines.

2. Non-Competitive antagonism: Irreversible binding with receptor preventing agonist binding to receptor, such as DFP which combines with acetylcholinesterase to prevent acetylcholine from binding to acetylcholinesterase.

O. **DRUG NOMENCLATURE**

1. Type of drug names
a. Chemical name: utilizes rules of organic chemistry.
b. Code name: assigned to drug by pharmaceutical manufacturer.
c. Generic name (nonproprietary name): if drug is admitted to United States Pharmacopoeia, the generic name becomes the official name of drug.
d. Tradename (proprietary name) (trademark) (registered name): a superscript R or TM follows trade name.
   1) If drug is marketed by more than one pharmaceutical company, then the same drug may have several trade names but only one official generic name.

2. Use of generic or tradename of a drug
a. Textbooks
b. Lectures, handouts and examinations in this course
c. National Board Examinations (USMLE)
d. Prescription of drugs
   1) A pharmacist may substitute a generic drug for a trade name drug unless the
      physician indicates "no substitution" on the prescription.
   2) The physician can indicate the manufacturer for a generic drug.
   3) Clinical application: Advantage of generic drugs is saving the patient
      money. Disadvantage of generic drugs is patient may receive a preparation
      of drug that is of inferior quality to a trade name drug.

e. Expressions of drug product equivalence related to generic drug substitution
   1) Chemical equivalence: related to amount of drug per tablet.
   2) Biological equivalence: related to pharmacokinetics involving
      bioavailability.
   3) Therapeutic equivalence: related to clinical response that will provide same
      efficacy and toxicity (hopefully same lack of toxicity).
      Clinical implications: most of the generic drugs are comparable in their
      safety and efficacy profile with the branded products. Very few exceptions.

P. DRUG-TESTING AND APPROVAL

1. Pre-clinical testing and toxicology screen
2. Phase I: 10 normal volunteers receive small doses and observed for efficacy and safety
3. Phase II: Small group of patients with disease and observed for efficacy and safety
4. Phase III: large-scale clinical trial in patients with disease and observed for best dosage for
   treatment of disease.
5. NDA (New Drug application): If the FDA approves the NDA, then the drug goes on the
   market for general use.
PHARMACOKINETICS I: ABSORPTION AND DISTRIBUTION

Learning Objectives

By the end of the lecture, you should be able to:
1. Define pharmacokinetics according to the acronym ADME.
2. Discuss the mechanisms (aqueous & lipid diffusion, active transport, etc.) by which drugs are absorbed in the body to reach their sites of action.
3. Describe chemical characteristics of drugs (e.g. solubility, pKa) and other factors (e.g. regional differences in blood flow, transporters, non-specific binding) that influence drug absorption.
4. Compare common routes of drug administration, their uses and their limitations.
5. Explain what is meant by a one-compartment and a two-compartment model of drug distribution and how it affects the plasma drug concentration time course.
7. Recognize that differential drug distribution can create drug reservoirs that affect the time course and magnitude of drug effect.

Drugs used as examples: digoxin, lidocaine, gentamicin, tobramycin, vancomycin, theophylline, warfarin, heparin, phenytoin, chloroquine, lidocaine, procainamide, penicillin G, aspirin, ethyl alcohol, propranolol

Recommended Reading:
The Merck Manual Online
Robert S. Porter, MD, Editor, Justin L. Kaplan, MD, Senior Assistant Editor
http://www.merck.com/mmpe/sec20/ch303/ch303a.html

Goodman & Gilman’s Manual of Pharmacology and Therapeutics, Chapter 2
Randa Hilal-Dandan, PhD, Laurence Brunton, PhD, Editors

An Outline of Topics for Review

1. Definition of Pharmacokinetics

2. Significance of pharmacokinetic principles in therapeutics:
   a. Design of rational therapeutic regimens.
   b. The time-course of drug action.
   c. Dose- (and/or plasma concentration-) related efficacy and toxicity. How to adjust dosage to achieve therapeutic efficacy and avoid toxicity.
   d. Significance of the area under the plasma concentration vs. time curve.

3. Factors affecting drug absorption:
   a. membrane permeability.
   b. availability of transport processes (active or passive).
   c. available surface area.
   d. pH and concentration gradients.
4. Routes of administration:
   a. oral
   b. sublingual/buccal
   c. rectal
   d. inhalation
   e. topical
   f. transdermal
   g. subcutaneous
   h. intramuscular
   i. intravenous
   j. intrasynovial
   k. intrathecal
   l. vaginal
   m. urethral
   n. ocular
   o. nasal
   p. aural
   q. intra-peritoneal
   r. epidural

   Enteral (administration through the digestive tract)

   Parenteral (given by routes other than the digestive tract, usually injected)

5. Factors affecting drug distribution:
   a. regional differences in blood flow
   b. tissue mass
   c. transport mechanisms
   d. permeability characteristics
   e. ion-trapping
   f. protein binding

6. One-compartment vs. Two-compartment distribution:
   a. One-compartment: a rapid equilibrium is achieved between plasma and tissue distribution following drug administration. Plasma concentration-time profile declines mono-exponentially.

   b. Two-compartment: rapid distribution to a central compartment is followed by slow distribution to other tissues(binding sites (second compartment). This results in a bi-exponential plasma concentration-time profile. With repetitive administration, steady-state concentrations are achieved only after 5-6 elimination half-lives ($t_{1/2}$). Digoxin, lidocaine, and phenytoin are examples of drugs that display two-compartment pharmacokinetics.

7. Volume of Distribution ($V_d$)

   $V_d$ describes how large a blood volume would be required to contain the entire administered dose at the measured concentration of drug in the blood.

8. Drug Reservoirs

   Accumulation of drugs in tissues (e.g. fat & muscle) can prolong drug action.
DEFINITION OF PHARMACOKINETICS

Pharmacokinetics relates the time courses of a drug’s absorption, distribution, and elimination (metabolism & excretion) to the intensity and time course of its pharmacological (therapeutic and/or toxic) effects.

CONSIDERATIONS FOR RATIONAL DESIGN OF A THERAPEUTIC REGIMEN:
- Dose
- Absorption
- First-pass Metabolism
- Volume of Distribution and Elimination clearance
- Area under the curve (AUC)
- Compliance
AREA UNDER THE CURVE (AUC)

Clinical Significance:

- Used to compare amount of drug that reaches the systemic circulation by different routes of administration: determine bioavailability (F).
- Used to compare clearance (CL) of a drug in different individuals after administration of the same dose via the same route.

\[
\text{CL} = \frac{\text{DOSE i.v.}}{\text{AUC}} \quad \text{CL/F} = \frac{\text{DOSE p.o.}}{\text{AUC}}
\]

DRUG ABSORPTION

Definition:
The processes by which drugs move from their site of administration to the plasma.

Processes following oral drug administration:

- disintegration of solids and dissolution of drug in fluids of gastrointestinal tract
- passage of drug across or between cells to reach the systemic circulation.

Factors affecting drug absorption:

- chemical composition of drug and delivery formulation (tablet, capsule, solvent, etc)
- regional differences in blood flow
- transport mechanisms
- permeability characteristics
- ion-trapping
- nonspecific binding

I. Passage of drugs across membranes

A. Aqueous diffusion

1. small molecules (<100 kD mol. weight)
2. passive process

B. Lipid diffusion

1. passive process
2. driven by concentration gradient:
   the greater the difference across the membrane the more rapid the rate of crossing
3. lipid solubility is important
   a. the more lipid soluble the faster the rate of transport
   b. lipid solubility is affected by the degree of ionization
   c. degree of ionization is dependent upon pH
      
      \[i. \text{can be determined at a given pH by using the Henderson-Hasselbalch equation}\]
ii. this is not a linear relationship

iii. important to remember that the pH at which 50% of the compound is ionized is by definition the pKₐ

<table>
<thead>
<tr>
<th>For Acids</th>
<th>For Bases</th>
</tr>
</thead>
<tbody>
<tr>
<td>$pK_a = pH + \log \frac{[A\text{H}]}{[A^-]}$</td>
<td>$pK_a = pH + \log \frac{[BH^+]}{[B]}$</td>
</tr>
</tbody>
</table>
Ion trapping:
The concentration of the non-ionized form of a drug will tend to equilibrate across compartments because this form can permeate lipid membranes. However, the fraction of ionized drug described in the Henderson-Hasselbalch relationship will be established within each compartment based on the difference between compartmental pH and drug pK_a. Because the ionized form cannot readily permeate lipid membranes, the drug can become trapped, resulting in a greater concentration in compartments that favor its ionized form. Weak acids become more concentrated in more alkaline compartments; weak bases tend to concentrate in more acidic compartments.

4. surface area:

the greater the surface area the faster the rate of transport

C. Active transport

1. requires expenditure of cellular energy

2. unidirectional

3. structural specificity

D. Minor mechanisms

1. facilitated diffusion

2. pinocytosis
II. Different routes of drug administration

A. Enteral

1. Oral

   a. Physical form of drug can be of many types.

   b. Local differences in pH affect absorption.

   c. Differences in surface area can determine primary sites of absorption.

   d. The fraction (F) of the orally administered dose that reaches the systemic circulation in its active form is called its oral bioavailability.

   A drug may have less than 100% bioavailability if it is incompletely absorbed or if it undergoes metabolism, e.g. while going through the liver via the portal circulation (first-pass metabolism).

   Oral bioavailability may be estimated by comparing AUC for the orally administered drug AUC for the same dose of drug given to the same patient intravenously.

   \[
   F_{\text{oral}} = \frac{\text{AUC}_{\text{p.o.}}}{\text{AUC}}
   \]

   First-pass effect:

   *Some drugs have such a high rate of metabolism that no drug ever enters the systemic circulation even though it is completely absorbed.*

   Oral doses may be higher than parenteral doses because of reduced bioavailability (F<1):

   \[
   \text{Dose}_{\text{p.o.}} = \frac{\text{Dose}_{\text{i.v.}}}{F_{\text{oral}}}
   \]

   e. Enterohepatic circulation:

   *Some drugs are absorbed, transported to the liver, and secreted into the bile. They are then deposited back into the intestine and can be reabsorbed.*

   f. Alterations in gastric emptying time can delay or speed up absorption.

   *Prolonged times to gastric emptying time will generally result in delayed absorption.*

   *Some drugs can directly affect emptying time.*

---

1A similar dosage adjustment is required when a drug is prepared in a formulation that provides a fraction of the total weight of drug as active drug and the remainder as an inactive salt. The fraction of total drug that will be delivered as active drug to the systemic circulation is called the “salt factor” (S). The appropriate dose is determined by dividing the desired dose of active drug by the salt factor.
2. Sublingual/buccal
   a. advantages
      will not be absorbed into the portal system
      a higher pH than found in the stomach
   b. disadvantages
      drug taste

3. Rectal
   a. advantages
      50-60% will by-pass the portal vein & avoid first-pass hepatic metabolism
      useful in cases of nausea and vomiting
   b. disadvantages
      discomfort, inconvenience, etc.

B. Inhalation
   1. passive diffusion
   2. large surface area
   3. volatile gases
      driven by differences in partial pressures
   4. aerosol preparations
      site of absorption dependent on particle size
   5. drug absorption varies with depth and duration of inspiration
      may be necessary to titrate to desired effect or use metered inhaler

C. Topical
   1. mostly for non-systemic use
   2. highly lipid soluble compounds will reach general circulation
   3. common forms include creams, lotions, gels, ointments, shampoos
D. Transdermal

1. passive diffusion of drugs across the skin—driven by concentration gradient

2. potential benefits:
   a. controlled release of the drug into the patient—enables a steady blood-level profile
   b. user-friendly, convenient, painless, multi-day dosing—improved patient compliance
   c. bypassing the gastrointestinal (GI) tract obviates GI irritation that occurs with some drugs and avoids partial first-pass inactivation by the liver

3. limitations/risks:
   a. skin barrier limits the number of drugs that can be delivered by passive diffusion from an adhesive patch
   b. potential skin irritation, discomfort

E. “Parenteral” (not via the digestive tract), often used to describe administration of drugs by injection

importance of blood flow:

Blood flow to the area maintains the concentration gradient (the drug is removed by the circulating blood, so its concentration will remain lower in the local blood vessels than on the tissue side at the site of injection). This helps maintain a steady rate of absorption until the local reservoir at the site of injection becomes depleted.

advantages

greater degree of reliability and precision of administered dose

fewer problems with absorption

  *do not have to worry about presence or absence of food in the stomach*

  *do not have to worry about "first-pass effect"*
disadvantages

sight of the needle

pain

tissue damage and irritation

drug must be in solution form

1. subcutaneous (sc)
   a. advantages
      i. a slow even absorption
      ii. may be used as a depot
      iii. rate of absorption can be modified by altering blood flow
   b. disadvantages
      i. is of little value in peripheral circulatory failure (shock)
      ii. only small volumes can be accommodated

2. intramuscular (im)
   a. advantages
      i. a more rapid absorption than seen with sc
      ii. as with sc administration, rate of absorption can be modified by altering blood flow
   b. disadvantages
      i. potential infection and/or nerve damage
      ii. danger of inadvertent iv administration

3. intravenous (iv)
   a. advantages
      fastest and most reliable way of achieving a specific blood level
   b. disadvantages
      to avoid a bolus effect (an excessively high plasma concentration achieved by rapid i.v. drug administration) it may be necessary to administer the dose over a longer period of time
F. Other parenteral:

1. intrasynovial (within the synovial sac of a joint, or the synovial sheath of a tendon)
2. intrathecal (through the theca of the spinal cord into the subarachnoid space)
3. vaginal
4. urethral
5. ocular
6. nasal
7. aural
8. intraperitoneal
9. epidural (into the epidural space of the spinal column)

III. Distribution of absorbed drug

A. Factors influencing distribution

1. regional differences in blood flow
2. tissue mass
3. transport mechanisms
4. permeability characteristics

   *some membranes are more resistant to drug passage than others, e.g. blood-brain barrier, blood-testis barrier, and placental barrier*

5. ion-trapping

   *drug can be trapped in a body compartment due to a local pH differences*

6. protein-binding

   • many drugs bind reversibly to plasma proteins.
     – *albumin binds acidic drugs*
     – *α1 acid glycoprotein binds basic drugs*
   • protein-bound drugs are retained in the plasma.
B. One- vs. Two-compartment Distribution

1. One-compartment: a rapid equilibrium is achieved between plasma and tissue distribution following drug administration. Plasma concentration-time profile declines mono-exponentially.

2. Two-compartment: rapid distribution to a volume represented by a central compartment (usually plasma, $V_P$) is followed by slow distribution to tissues/peripheral binding sites (second compartment; $V_T$). This results in a bi-exponential plasma concentration-time profile. With repetitive administration, steady-state concentrations are achieved only after 5-6 elimination half-lives ($t_{1/2}$). Digoxin, lidocaine, and phenytoin are examples of drugs that display two-compartment pharmacokinetics.
C. Volume of distribution

1. When a drug is administered it distributes to various body compartments.

2. Volume of distribution ($V_d$) is a measure of how much of the administered dose distributes outside of the plasma.

3. $V_d$ describes how large a blood volume would be required to contain the entire administered dose at the concentration of drug in the plasma at $t=0$ ($C_0$).

$$V_d = \frac{Dose}{C_0}$$
If you administer a dose $D$ of a drug, the initial plasma concentration ($C_0$) of the drug depends on the volume into which the drug distributes:

$$C_0 = \frac{D}{V_d}$$

The volume of distribution ($V_d$) quantifies that by specifying how large a volume would be needed in order to observe the plasma concentration actually measured.

For example, consider a case in which $D = 6 \text{ mg/kg}$. A human has a plasma volume ($V_{\text{plasma}}$) of around $0.06 \text{ l/kg}$. This gives a $C_0 = 100 \text{ mg/liter}$ if the drug stays in the blood stream only, and thus its volume of distribution is the same as $V_{\text{plasma}}$, that is $V_d = 0.06 \text{ l/kg}$. If the drug distributes into total body water, the volume of distribution would increase tenfold, to approximately $0.6 \text{ l/kg}$.

If the drug readily diffuses into the body fat the volume of distribution may increase dramatically. An example is chloroquine, which has a $V_d = 200$-$300 \text{ l/kg}$.

In the case of one-compartment distribution, the volume of distribution is defined as: $V_d = D/C_0$, where $C_0$ is the measured plasma concentration immediately after the drug is administered. In the two-compartment case, $C_0$ is an extrapolated concentration at time $= 0$, extrapolated from the linear portion of the log plasma concentration vs. time plot.

<table>
<thead>
<tr>
<th>Drug</th>
<th>$V_d$ (l/kg)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin</td>
<td>0.05-0.1</td>
<td>Reflects a high degree of plasma protein binding.</td>
</tr>
<tr>
<td>Theophylline, Ethanol</td>
<td>0.4-0.9</td>
<td>Reflects distribution in total body water.</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>200-300</td>
<td>Highly lipophilic drug that distributes into total body fat.</td>
</tr>
</tbody>
</table>
NOTE: The apparent Volume of Distribution is a theoretical number that may not correspond to an actual physiological space. Actual physiological volumes into which drugs distribute are often much smaller.

A drug which passes through cell membranes, is not bound to any tissue constituent or taken up into any particular cells (i.e. it is evenly distributed in total body water) would have a $V_d = 0.6$ L/kg (42 L/70 kg).

A drug which passes through capillary endothelium but not through cell membranes, and is not protein-bound or extremely lipid soluble may only be distributed in extracellular fluid and have a $V_d = 0.14$-0.2 L/kg (10-15 L/70 kg).

A drug which is tightly bound to plasma protein, would have a $V_d$ equivalent to that of plasma water, $V_d = 0.06$ L/Kg (4 L/70 kg).
Protein binding affects the apparent Volume of Distribution

An increase in the unbound fraction of total [drug] (e.g. in hypoalbuminemia) will result in an increase in the apparent volume of distribution ($V_d$).

\[
V_d = V_P + \left( \frac{V_T \times f_{uT}}{f_{uP}} \right)
\]

where $V_d$ = volume of distribution, $V_P$ and $V_T$ are plasma and tissue volumes, respectively. Note: $V_T$ and fraction unbound in tissues ($f_{uT}$) cannot be determined easily. A reasonable approximation of $V_T$ can be made by estimating tissue water volume ($V_{TW}$). For a 70 kg man, $V_{TW} = $ total body water - plasma water $\approx 42L - 4L = 38L$

For example, consider a drug that is 90% bound to plasma albumin (10% unbound in the plasma). If the volume of distribution under these conditions is $14L$, the value of $V_T$ divided by $f_{uT}$ will be $100L$ (assume $V_P = 4L$). Assuming no other parameters change, a drop in plasma [albumin] that decreases the fraction of bound drug to 80% (20% unbound in plasma) will increase $V_d$ to $\approx 24L$:

\[
V_d = V_P + [(V_T/f_{uT}) \times f_u] \\
14L = 4L + [(V_T/f_{uT}) \times 0.1] \\
10L = [(V_T/f_{uT}) \times 0.1] \\
(V_T/f_{uT}) = 100L \\
V_d = V_P + [(V_T/f_{uT}) \times f_u] \\
= 4L + (100L \times 0.2) = 24L
\]
D. Drug Reservoirs

- Following absorption, drugs in the systemic circulation are distributed to peripheral tissues.
- Distribution is bi-phasic: an initial distribution to organs with rich blood supply (kidney, liver, heart, lungs, brain), followed by distribution to other tissues with less rich blood supply (fat, muscles, bone, bladder).
- Different drugs distribute differently. For example, the anesthetic thiopental, a highly fat-soluble drug, rapidly enters the brain, but the antibiotic penicillin, a water-soluble drug, does not. Fat-soluble drugs such as thiopental tend to concentrate in adipose tissue. Bone can accumulate environmental toxins such as lead or drugs such as tetracycline antibiotics. Some drugs have a very narrow distribution profile, because specific tissues have a particularly high affinity for the drug (for example, iodine concentrates mainly in the thyroid gland).
- Fat and muscle in particular can act as drug reservoirs. Ultimately large amounts of a drug can accumulate in these tissue reservoirs, especially in obese patients. In some cases more drug may be stored in these tissues than remains in the systemic circulation.
- Deposition into any reservoir limits the fraction of the drug available for diffusion from the plasma to site of action as well as to sites of excretion (or metabolism).
- When plasma levels of the drug decline due to metabolism or excretion, they are replenished by diffusion from the reservoir. Gradual release of drug from these sites can prolong the therapeutic effect or result in toxicity if drug administration is continued.
- A reservoir may need to be saturated with the drug before a therapeutic effect is manifest. In this case a large dose may be needed to provide an effective concentration at the site of action of the drug.
- Plasma proteins can also serve as a drug reservoir. For a highly protein-bound drug, a large fraction of administered drug may be retained in the plasma because only the unbound drug molecules can cross cell membranes. In its protein-bound state the drug may not be distributed to its site of action. When the drug dissociates from plasma protein (the dissociation rate will depend primarily on its affinity for the protein) it will then be free to distribute to exert its effects.
- Many different drugs bind to sites on plasma albumin, so competition can occur between them. Theoretically, administration of drug B can reduce the protein binding, and hence increase the free plasma concentration of drug A. To do this, drug B needs to occupy an appreciable fraction of the protein binding sites. Few therapeutic drugs affect the binding of other drugs to albumin because they occupy, at therapeutic plasma concentrations, only a tiny fraction of the available sites. Sulfonamides are an exception because they occupy about 50% of the binding sites at therapeutic concentrations and so can cause unexpected effects by displacing other drugs.
PHARMACOKINETICS II: DRUG ELIMINATION & MULTIPLE DOISING

Learning Objectives

By the end of the lecture, you should be able to:

1. Explain the difference between first-order, zero-order and dose-dependent kinetics of drug elimination.
2. List examples of commonly used drugs that follow zero-order, first-order and dose-dependent kinetics.
3. Recognize the importance of steady-state plasma drug concentrations for maintenance therapy and describe the time course for achieving steady state with intermittent dosing or continuous infusion.
4. List the primary pharmacokinetic parameters and describe how they are used to determine appropriate loading dose and maintenance dose.
5. Interpret the effects of altered distribution or clearance of drugs on plasma drug concentrations and formulate an appropriately adjusted dosing strategy.
6. Discuss the roles of the kidney and liver in the elimination of drugs from the body.

Recommended Reading:

The Merck Manual Online
http://www.merck.com/mmpe/sec20/ch303/ch303a.html

Goodman & Gilman’s Manual of Pharmacology and Therapeutics, Chapter 2
Randa Hilal-Dandan, PhD, Laurence Brunton, PhD, Editors

An Outline of Topics for Review

1. Review the plasma concentration versus time curve.
   a. Distribution phase.
   b. Elimination phase.

2. Review the apparent volume of distribution (V_d).
   a. The dilution principle
   b. Why is V_d larger than anatomically possible (for some drugs)?

3. The loading dose.
   a. Definition
   b. Rationale
   c. Dependence on V_d

4. The maintenance dose.
   a. Definition
   b. Rationale
   c. Dependence on CL_E
5. The concept of steady-state.
   a. The plateau principle.
   b. Dependence of eventual steady-state levels on the maintenance dose and not on the loading dose.

6. Drug administration by continuous infusion.
   Estimation of clearance from the infusion rate and the steady-state plasma concentration (CL = I / C_s).

   a. First-order kinetics.
   c. Dose-dependent kinetics.
   d. Examples of drugs that are eliminated by these types of kinetics.

8. Elimination clearance (CLₑ).
   a. Definition.
   b. The relationship of k and t½ to clearance.

9. Elimination half-life: Clearance and Volume of Distribution as primary pharmacokinetic parameters
   a. k a dependent parameter (k = Cl/Vd)
   b. t½ a dependent parameter (t½ = 0.69 Vd/CL)

10. Renal Insufficiency.
   a. Affects on Clearance
   b. Adjustment of dosing rate.

11. Hepatic Clearance.
   b. Restrictive hepatic clearance (CL_H = f • CL_int).
   c. Non-restrictive hepatic clearance (CL_H = Q).
MAINT ENANCE DOSING

- Dosing strategy to maintain a steady-state concentration of drug in the body.

- Dose is based on replacing the amount of drug cleared from the body since the previous drug administration.

\[ \text{MD} = \text{CL} \times \text{TC} \times \frac{T}{F} \]

- Clearance is the primary determinant for calculating the maintenance dose.

STEADY-STATE CONCENTRATION

- A function of dosing rate and elimination clearance
- Rate of drug administration = rate of drug elimination
- Continuous I-V infusion:
  - Steady-state attained after approximately four elimination half-lives
  - Time to steady-state independent of dosage

\[ C_{ss} = \frac{\text{Dosing Rate}}{\text{Clearance}} \]

\[ \text{Infusion rate} = CL \times C_{ss} \]
KINETICS OF DRUG ELIMINATION

FIRST-ORDER KINETICS OF DRUG ELIMINATION
- 1st-order elimination (or kinetics): the elimination rate of the drug is a constant fraction of the drug remaining in the body (rather than a constant amount of drug per hour).
- Elimination half-life \((t_{1/2})\) is constant.
- Most drugs used clinically obey 1st order kinetics.

ZERO-ORDER KINETICS OF DRUG ELIMINATION
- Drugs that are eliminated primarily by metabolism may display zero-order kinetics of elimination.
- When metabolic pathways are saturated, metabolism occurs at a fixed rate, i.e. it does not change in proportion to drug concentration.
- A fixed amount of drug is metabolized per unit time (zero-order kinetics).
DOSE-DEPENDENT KINETICS OF DRUG ELIMINATION

- When a drug’s elimination is mediated predominantly by metabolism, its elimination will tend to follow first-order kinetics when concentrations are well below the $K_M$ of the metabolic enzymes, but will follow zero-order kinetics at doses that greatly exceed the $K_M$ of the metabolic enzymes.
- Common examples include phenytoin, ethanol, and aspirin.

DOSE-DEPENDENT ELIMINATION RATE

\[
\frac{dC}{dt} = -\frac{V_{MAX} \cdot C}{K_M + C}
\]

ELIMINATION CLEARANCE

- Volume of plasma cleared of drug per unit time. Units are ml/min or L/hr (“flow”).
- Drug elimination may occur through the kidneys, the liver, the lung, and other organs.
- Total Clearance is equal to the sum of all these individual and simultaneously occurring organ clearances:

\[
CL_{total} = CL_{renal} + CL_{hepatic} + CL_{other}
\]

ELIMINATION HALF-LIFE

Time to eliminate 50% of the body content of the drug—it is a function of both Clearance and Volume of Distribution.

\[
t_{\frac{1}{2}} = \frac{0.69 \cdot V_d}{CL} = \frac{0.69}{k}
\]

RENAAL FAILURE

- Impaired renal function often results in reduced clearance of drugs that are eliminated primarily by the kidneys.
- Dosing rate must be reduced by the ratio of measured clearance in renal failure ($CL_{RF}$) to expected normal, average clearance ($CL_N$).
- The dosing rate may be reduced by decreasing the dose, increasing the dosing interval, or both.
- Creatinine clearance ($CrCL$), estimated using the Cockcroft & Gault equation, can provide an assessment of renal function. The ratio of CrCL in renal failure to CrCL in a patient with normal renal function can also be used to adjust the dosing rate. Creatinine clearance is not the same as clearance of a drug.

\[
CrCL (ml/min) = \frac{(140 - \text{age}) \times \text{wt (kg)}}{72 \times [\text{serum Cr (mg/dL)}]} \times 0.85
\]

Dosing Rate$_{RF} = $ Dosing Rate$_{Normal} \times -$
HEPATIC CLEARANCE

Determined by:

1. Hepatic Blood Flow (rate of drug delivery to the eliminating organ).
2. Plasma Protein Binding (fraction of drug available for clearance).
3. Intrinsic Clearance (hepatocellular metabolism and/or biliary excretion).

1. RESTRICTIVE HEPATIC CLEARANCE
   - Drugs with low hepatic extraction ($Q >> f \cdot CL_{int}$)
   - Little "first pass metabolism" when given orally.
   - A change in binding or drug metabolism/excretion activity will have a greater effect on hepatic clearance than changes in liver blood flow. Capacity-limited clearance.
   - Examples: warfarin, phenytoin

   \[
   CL_H = f \cdot CL_{in}
   \]

2. NON-RESTRICTIVE HEPATIC CLEARANCE
   - Drugs with high hepatic extraction ($Q << f \cdot CL_{int}$)—extensive first pass metabolism.
   - Hepatic clearance is sensitive to changes in liver blood flow and less sensitive to alterations in binding or intrinsic clearance. Flow-dependent clearance: conditions that reduce hepatic blood flow (CHF, hypotension) will reduce hepatic clearance.
   - Examples: lidocaine, propranolol

   \[
   CL_H = Q
   \]

The Rowland’s Equation:

\[
CL_H = Q \left[ \frac{f \cdot CL_{int}}{Q + f \cdot CL_{int}} \right]
\]

$Q \equiv$ Liver blood flow  
$f \equiv$ Free Fraction (unbound)  
$CL_{int} \equiv$ Intrinsic Clearance
BASIC CONCEPTS IN PHARMACOKINETICS

Pharmacodynamics: A major subdivision of pharmacology dealing with the actions and the mechanisms of action of drugs (i.e., the concepts of drug-receptor interactions and the dose-response relationship are studied under pharmacodynamics).

Pharmacokinetics: The other major subdivision of pharmacology, dealing with the quantitative description of absorption, distribution, metabolism and elimination of drugs (i.e., pharmacokinetics provides the scientific basis for dose selection and also deals with the time-course of drug action).

Bioavailability: For drugs given orally, it is defined as the fraction of the administered dose that reaches the systemic circulation unchanged. A drug may have incomplete bioavailability (less than 100%) if it is incompletely absorbed or if it undergoes metabolism while going through the liver via the portal circulation (first-pass metabolism). Some drugs have high bioavailability (e.g., 90-100% of a dose of warfarin, phenytoin, theophylline or digitoxin will reach the systemic circulation unchanged after oral administration). Other drugs will undergo extensive first-pass metabolism in the liver and will have a low bioavailability when given orally (e.g., about 30-35% of a dose of lidocaine or propranolol will reach the systemic circulation unchanged after oral administration).

Apparent Volume of Distribution: A primary pharmacokinetic parameter used to relate the dose administered to the resulting plasma concentration of drug. This parameter is calculated in reference to plasma concentration of drug, and may be large or small (sometimes much larger than anatomically possible), depending on the tissue:plasma partition ratio for the drug in question (e.g. the apparent volume of distribution for digoxin is of the order of 9.8 liters/kg body weight, which in a 70 kg individual would amount to a total apparent volume of distribution of 686 liters, reflecting the much higher affinity of digoxin for tissues than for plasma). Knowledge of the apparent volume of distribution is important for the appropriate calculation of loading doses. The apparent volume of distribution is also a primary determinant of the drug’s elimination half-life ($t_{1/2}$).

Apparent Volume of Distribution ($V_d$) = Loading Dose/$C_0$ (initial concentration)

When given intravenously, drugs distribute at different rates from the intravascular compartment to the peripheral target tissues. For example, plasma lidocaine is in equilibrium with tissue lidocaine in 30-60 minutes, whereas other drugs distribute more slowly (e.g. plasma digoxin does not reach equilibrium with tissue digoxin for at least 6-8 hours after an i.v. dose). This is relevant to the proper interpretation of plasma concentrations of drugs. For drugs that distribute slowly, the elimination phase of the plasma concentration vs. time plot should be extrapolated back to the zero time axis to determine $C_0$ for $V_d$ calculations.
Clearance: The other primary pharmacokinetic parameter, clearance determines the rate of drug elimination. Just as, for example, creatinine clearance, the clearance of a drug may be defined as the volume of plasma that is cleared of drug per unit time. Some drugs undergo only renal clearance (e.g. gentamicin, tobramycin, vancomycin), some are eliminated only via hepatic clearance (e.g. theophylline, warfarin, phenytoin, lidocaine), and others undergo both renal and hepatic clearance (e.g. digoxin, procainamide, penicillin G). The term nonrenal clearance is often used to include hepatic clearance and any other extrarenal route of clearance for a drug. Renal and nonrenal clearances are additive, such that:

Clearance of elimination = Renal clearance + Nonrenal clearance

Clearance of elimination is another major determinant of a drug’s elimination half-life (t½).

Elimination Half-Life (t½): This concept is applicable to drugs that follow first-order kinetics of elimination. It is defined as the time required to eliminate one-half (50%) of the body content of a drug. It is important to note that elimination half-life is dependent on both the apparent volume of distribution and the clearance of elimination, according to the following relationship:

\[ t_{\frac{1}{2}} = \frac{0.69 \times \text{Apparent Volume of Distribution}}{\text{Clearance of Elimination}} \]

Volume of distribution and clearance are the primary parameters and are biologically independent of each other. Thus, half-life could change if either or both volume of distribution and clearance change. Consequently, t½ reflects rate of drug clearance only when volume of distribution is constant (congestive heart failure appears to reduce both the apparent volume of distribution and the clearance of lidocaine, so that the t½ of this drug may appear normal and may be misleading in the choice of the proper infusion rate; the reduced volume of distribution also requires a reduction in the loading doses).

Steady-State Concentrations: With continuous drug administration (maintenance therapy) by either constant rate i.v. infusion or constant oral dosing rate (e.g., lidocaine infused at a rate of 2 mg/min i.v., or digoxin given orally at a dosing rate of 0.25 mg/day), most drugs will accumulate exponentially until a plateau or steady-state concentration is reached. With dosing at a constant interval, concentrations will fluctuate above and below the steady-state concentration. Once steady-state has been achieved (the rate of drug administration is equal to the rate of drug elimination), the following relationship applies:

\[ \text{Steady-State Concentration} = \frac{\text{Dosing Rate}}{\text{Elimination Clearance}} \]

Thus, there is a directly proportional relationship between the dosing rate and the steady-state plasma concentration. This is true for most drugs used in clinical medicine, since most drugs follow first-order kinetics of elimination (the rate of drug elimination is proportional to the amount of drug present in the body).

Some drugs like phenytoin, aspirin and ethyl alcohol are exceptions to the rule in that they follow dose-dependent kinetics of elimination. At low doses and plasma concentrations, they follow apparent first-order kinetics, but at higher doses and plasma concentrations the metabolic
pathways become saturated and the drugs exhibit zero-order kinetics of elimination (a constant amount of drug is eliminated per unit time; drug metabolism is capacity-limited and is not proportional to the amount of drug present in the body). Thus, changes in the dosing rate may result in disproportionate, non-linear changes in drug concentrations, and toxicity may develop.

With first-order kinetics, if the dosing rate is doubled, the steady-state concentration will double. With dose-dependent kinetics, doubling the dose may result in tripling or quadrupling the steady-state concentration, with the attendant risk of toxicity.

**Maintenance Dosing:** Maintenance dosing is a regimen whereby a drug is administered at regular intervals (or continuously infused) to achieve a steady-state plasma concentration. Once steady-state is achieved, the maintenance dose matches the amount of drug cleared since the previous dose was administered (or the infusion rate matches the rate of elimination). Maintenance dosing is therefore dependent on the clearance of elimination according to the formula:

\[ MD = CL \times TC \times T/F \]

where \( MD \) = maintenance dose (e.g. in mg), \( CL \) = clearance of elimination (units of flow, e.g. L/hr), \( TC \) = target concentration (at steady-state; units of concentration, e.g. mg/L), \( T \) = interval (units of time, e.g. hr), and \( F \) = bioavailability.

An alternative representation of this relationship is that the maintenance dosing rate (dose/interval) equals the product of clearance and target concentration:

\[ F \times MD \text{ rate (mg/hr)} = CL \times TC = \text{infusion rate (for continuous i.v. administration)} \]

The time to reach the steady-state target concentration is approximately 4-6 elimination half-lives. At steady-state the plasma concentration can be adjusted by a proportional change in maintenance dose (if the clearance and interval are constant and assuming first-order kinetics of elimination). For example, doubling the maintenance dose would double the plasma concentration (but it would take 4-6 elimination half-lives to achieve the new steady-state).

When the drug is administered at regularly spaced intervals, the plasma concentrations will fluctuate above and below the steady-state concentration. The magnitude of the fluctuations will be directly proportional to the ratio of interval to the elimination half-life.

In some cases, a **loading dose** may be given to more rapidly achieve a therapeutic plasma concentration. The loading dose is dependent on volume of distribution rather than clearance and is intended to rapidly achieve a specific concentration of drug:

\[ LD = V_d \times TC/F \]

where \( LD \) = loading dose (e.g. in mg), \( V_d \) = volume of distribution (e.g. in L), \( TC \) = target concentration (e.g. in mg/L), and \( F \) = bioavailability.

If drug levels are measured and found to be inadequate, a new target concentration can be rapidly achieved using an adjusted loading dose formula:

\[ LD = V_d \times (TC - C_{measured})/F \]
There is no interval specified in the loading dose formula because it does not take into account the clearance of elimination. Therefore the loading dose formula cannot strictly be used to specify a maintenance dosing regimen—the time it takes for the concentration to decline from the calculated target concentration is not figured into the equation. A maintenance dosing regimen, based on the clearance of elimination, is normally initiated at its specified dosing interval (T) after the loading dose.

**Time to Reach Steady-State:** With continuous or repetitive drug administration, it is useful to know that 90% of the eventual steady-state concentrations will be achieved in a time equal to 3.3 elimination half-lives ($t_{0.90} = 3.3 \ t_{1/2}$). The longer the $t_{1/2}$, the longer it will take to reach steady-state.

If the clearance of a drug is decreased and the $t_{1/2}$ prolonged, for example, due to renal or hepatic disease, it will take longer to achieve steady-state concentrations, in proportion to the increase in $t_{1/2}$. Note that we are talking about the time required to reach steady-state, not the actual steady-state concentration that will be reached. The actual steady-state concentration will be a function of the dosing rate (i.e. mg/min, mg/day, etc.) and the elimination clearance (see above).
<table>
<thead>
<tr>
<th>Drug</th>
<th>Use</th>
<th>Some pharmacokinetic characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>aspirin</td>
<td>Analgesic, antipyretic, anti-inflammatory.</td>
<td>Approximates zero order kinetics of elimination at high concentrations.</td>
</tr>
<tr>
<td>digoxin</td>
<td>Atrial fibrillation, atrial flutter and congestive heart failure</td>
<td>Narrow therapeutic index, large Volume of Distribution ($V_d$), high bioavailability, two-compartment distribution profile.</td>
</tr>
<tr>
<td>ethyl alcohol</td>
<td>Makes you drunk.</td>
<td>Concentration-dependent kinetics of elimination; zero-order at high concentrations.</td>
</tr>
<tr>
<td>gentamicin</td>
<td>Aminoglycoside antibiotics, used to treat many types of bacterial infections, particularly Gram-negative bacterial infections</td>
<td>Cleared exclusively by the kidney, both can be highly nephrotoxic, particularly if multiple doses accumulate over a course of treatment—usually dosed by body weight and serum levels are monitored during treatment. Tobramycin does not pass the gastrointestinal tract, so for systemic use it can only be given intravenously or intramuscularly.</td>
</tr>
<tr>
<td>tobramycin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lidocaine</td>
<td>Local anesthetic and antiarrhythmic</td>
<td>Low bioavailability (extensive first-pass metabolism in the liver). Lidocaine hydrochloride is available in various forms including: injectable (for i.v. injection/infusion or as local anesthetic), dermal patch, nasal instillation/spray, oral (gel, liquid), topical (gel, liquid, or patch). Given i.v. it distributes rapidly to tissues. Eliminated primarily by metabolism in the liver. Two-compartment distribution profile.</td>
</tr>
<tr>
<td>penicillin G</td>
<td>Antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria.</td>
<td>Elimination rate is dependent on renal function and is greatly reduced in renal failure: $t_{1/2}$ can increase as much as 20-fold.</td>
</tr>
<tr>
<td>propranolol</td>
<td>$\beta$-blocker, mainly used in the treatment of hypertension.</td>
<td>Extensive first-pass metabolism (low bioavailability), lipid soluble, large $V_d$.</td>
</tr>
<tr>
<td>theophylline</td>
<td>A methylxanthine drug used in therapy for respiratory diseases such as COPD or asthma.</td>
<td>Theophylline has a narrow therapeutic index. It approaches zero-order kinetics of elimination at high concentrations. High bioavailability. Eliminated primarily by metabolism in the liver.</td>
</tr>
<tr>
<td>vancomycin</td>
<td>A glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria.</td>
<td>Vancomycin must be given intravenously, because it is not absorbed orally (it is a large hydrophilic molecule which partitions poorly across the gastrointestinal mucosa). It is eliminated by the kidney.</td>
</tr>
<tr>
<td>warfarin</td>
<td>Anticoagulant</td>
<td>Warfarin has a long half life. It may be given orally once per day, but it is highly protein-bound and often takes several days to reach therapeutic effect. High bioavailability. Eliminated primarily by metabolism in the liver.</td>
</tr>
</tbody>
</table>
$dC/dt$ MOST
Learning Objectives:

Upon completion of this lecture, the student should be able to:

1. Describe how patients’ characteristics can influence the four basic pharmacokinetic parameters of medications (Absorption, Distribution, Metabolism, and Elimination).
2. List factors involved in individualizing a dosing regimen and describe how deviations from standards can be anticipated.
3. Describe why steady state is essential for accurate dose adjustments.
4. Describe how drug interactions can be associated with pharmacokinetics and pharmacodynamics.
5. Apply the information presented in lecture to describe which pharmacokinetic parameter is impacted when given a medication nonspecific drug interaction scenario.
Learning Objectives:
Upon completion of this lecture, the student should be able to:

1. Describe how patients’ characteristics can influence the four basic pharmacokinetic parameters of medications (Absorption, Distribution, Metabolism, and Elimination).
2. List factors involved in individualizing a dosing regimen and describe how deviations from standards can be anticipated.
3. Describe why steady state is essential for accurate dose adjustments.
4. Describe how drug interactions can be associated with pharmacokinetics and pharmacodynamics.
5. Apply the information presented in lecture to describe which pharmacokinetic parameter is impacted when given a medication nonspecific drug interaction scenario.
Definitions:
Pharmacokinetics: How the body affects a drug.
Pharmacodynamics: How the drug affects the body.

I. Pharmacokinetic Principles
A Four main principles are associated with every pharmacological agent (see section I C).
   a. Familiarity with these principles for each medication is essential to ensure accurate
      patient dosing (HINT: memorize general rules with exceptions for specific drugs).
   b. Assess your patient (use your eyes!) and use available information.
      i. Physical
      ii. Laboratory
      iii. Radiological
      iv. Overall clinical response
B These principles provide a basis for “usual” doses but deviations occur within patients.
C Four pharmacokinetic principles:
   a. Absorption (A)
      i. How the drug gets into the body from the site of administration
      a. Bioavailability (F): Fraction of administered drug that reaches the systemic
         circulation
      i. Intravenous: F = 100%
      b. PKa and PKb
         i. Ionized versus nonionized form
         ii. Nonionized (non protonated) forms distribute more readily
         iii. pH of environment
            1. Certain drugs require an acidic or basic environment for absorption
            2. Itraconazole (azole antifungal) requires an acidic environment
            3. Didanosine (nucleoside reverse transcriptase inhibitor) requires a basic
               environment
      c. Site of administration
         i. Oral / Enteral
            1. F < 100% (some exceptions do occur)
            2. Function of GI tract
               a. Ileus (lazy or sluggish bowel tract)
               b. Bowel obstruction
               c. Intact versus impaired GI tract
               d. Most drugs are absorbed in stomach or first part of duodenum
            3. Tube feeds – where is the tip of the feeding tube located
               a. Gastrostomy tube
               b. Duodenal
               c. Jejunal tube (hint: not great for enteral absorption)
               d. Can the medication be given via a feeding tube?
                  i. Liquid formulations preferred
                  ii. Not all tablets may be crushed OR opened.
iii. Do not crush sustained release/controlled release drugs
(sometimes formulations can be dissolved in water)

(ii) Parenteral
1. Intravenous
   a. 100% bioavailability
   b. Avoids first pass effect
2. Intramuscular
   a. ≤100% bioavailability
   b. Avoids first pass effect
3. Less common parenteral routes
   a. Intrathecal, intraventricular
   b. Intraocular
   c. Intra-articular
4. Topical/Transdermal/ Subcutaneous
   a. ≤100% bioavailability
   b. Avoids first pass effect
   c. Thick skin versus thin skin impacts topical absorption
   d. Intact versus non-intact skin impacts topical absorption
   e. Skin temperature will affect absorption (e.g. fentanyl transdermal patches)

b. Distribution Vd (L/kg) (D)
   (i) Theoretical fluid volume needed to maintain the total absorbed drug amount in the plasma.
   (ii) Factors to consider if the drug will get where it needs to go?
      (a) Perfusion rate
         (i) Normal perfusion allows for organs such as the liver, kidney, heart, brain etc. to be exposed to the medication
         (ii) Impaired perfusion limits exposure
            1. Ischemia (physiologic versus pharmacologic)
            2. Higher doses may be required
      (b) Properties of the medication
         (i) Lipophilic - Adipose (i.e. vancomycin – an antibiotic)
         (ii) Hydrophilic - Extracellular fluid (i.e. aminoglycosides – antibiotic class)
         (iii) Other areas – Bone, eye
      (c) Physiologic barriers
         (i) Protein binding
            1. Low protein binding → generally large Vd
            2. High protein binding → Vd may be challenged
            3. Changes can potentially affect clinical response & drug disposition
            4. Albumin is often used as a clinical marker
         (ii) Blood Brain Barrier (BBB)
            1. Noninflamed meninges: tight web, minimal penetration
            2. Inflamed meninges: increased spaces, possibly better penetration
            3. Medications with decreased protein binding cross BBB easier
            4. Maximize dosing or consider alternate routes of administration (i.e. intraventricular)
(iii) Bone, Eye, Placenta

c. Metabolism (M): How a drug is broken down
   (i) Many drugs undergo some form of hepatic metabolism with breakdown into
       active or inactive metabolites.
       (a) Phase I: reduction oxidation, hydrolysis with Cytochrome P450
       (b) Phase II: Conjugation (glucuronidation, acetylation, sulfation)
   (ii) Interactions often present due to competition for metabolic pathway with
       Cytochrome P450 system being the most common pathway

d. Elimination (E)
   (i) Clearance relates the rate of elimination to the plasma concentration
   (ii) Clearance affects half-life ($t_{1/2}$)
   (iii) Clearance may be impaired with hepatic or renal dysfunction
       (a) Most drugs are renally eliminated.
           (i) Renal function deteriorates with age.
           (ii) Estimate of renal function made via Creatinine Clearance (CrCl)
               1. Cockcroft & Gault most common formula (mL/min)
               2. Most drug references list renal dose adjustment per CrCl (mL/min) as
                  defined above, however some drugs are now adjusted per estimated
                  glomerular filtration rate (eGFR).
                     a. eGFR is used as a marker for chronic kidney disease (CKD)
                     b. reports as mL/min/1.73m²
               3. CrCl will be different for healthy 30yo and healthy 80yo.
               4. Creatinine also comes from muscle.
               5. Calculation using actual serum creatinine in elderly patients may
                  overestimate true renal function.
   (iii) Acute versus chronic renal insufficiency
   (iv) Hemodialysis and hemofiltration
       1. May filter out drug
           a. Hydrophilic
           b. Small molecular size
       2. CrCl < 10 ml/min generally equates to end stage renal disease
   (v) Anticipate dose adjustment with deviations from ‘normal’ renal function
       (CrCl < 70-100 ml/min-clinically) due to prolonged $t_{1/2}$
       (b) Assess the patient in addition to the laboratory result
           (i) Serum creatinine may look normal after a dialysis session
           (ii) Serum creatinine may not be that elevated but patient may be anuric
       (c) Some medications will require dosing changes for hepatic dysfunction

(iv) Biliary and fecal elimination
    (a) Less common
    (b) Ceftriaxone (antibiotic) – primarily biliary elimination
    (c) Linezolid (antibiotic) – primarily fecal elimination
    (d) Dose adjustments are generally not needed

(v) Useful equations
    (a) $t_{1/2} = 0.693 / K$ (hr⁻¹)
    (b) $Cl$ (L/hr) = $K$(hr⁻¹) x $Vd$ (L)
II Population pharmacokinetics

A “Textbook” pharmacokinetics

a. General pharmacokinetic parameters based on clinical trials.
b. Basis for recommended dosing
c. Provide standard pharmacokinetic information with ranges
   (i) Gentamicin (antibiotic)
      (a) Vd 0.25L/kg (0.2-0.3L/kg); t½ 2h; <30% protein binding
      (b) Interpatient variability: renal function, hydration status
      (c) Intrapatient variability: clinical status
   (ii) Phenytoin (Dilantin®) (antiseizure medication)
      (a) Vd varies with age
      (b) Protein binding 90% - binds to albumin (variances with neonates/infants)
      (c) Interpatient variability: protein binding, metabolism

B Patients do not always behave like textbooks!!

a. You must assess patient’s individual pharmacokinetic parameters.
   (i) What is the best route? Will the patient absorb the medication?
   (ii) Will the drug get to where I want it to go? Is my patient dehydrated, edematous, cachectic or obese?
   (iii) How is his/her renal or liver function? Do I need to adjust the dose?
   (iv) How many doses did the patient receive?
b. Reference books / Internet health care information sites to serve as guides
   (i) Clinical pharmacology®
   (ii) Epocrates®, Rxlist®
   (iii) Lexicomp Drug Information®
   (iv) Micromedex®, Medscape®
   (v) Other reputable sources

C Examples of variations in pharmacokinetic parameters per age group

a. Neonates (<30 days of life)
   (i) Immature skin, increased skin hydration → increased absorption of topical products
   (ii) Increased extracellular fluid → higher volume of distribution of water soluble drugs (i.e. aminoglycosides)
   (iii) Metabolic pathways mature at different times
   (iv) Glomerular filtration, tubular secretion and reabsorption immature at birth
b. Elderly
   (i) Skin thinning → increased topical absorption
   (ii) Increased adipose tissue → increase in volume of distribution of fat soluble drugs
   (iii) Decreased extracellular fluid → decrease in volume of distribution of water soluble drugs
   (iv) Age related decrease in renal function
III Therapeutic Drug Monitoring (TDM)

A Starting dose for drugs requiring TDM are designed based on population pharmacokinetics. Adjustments are made utilizing patient specific pharmacokinetic parameters calculated from patient specific drug levels.

B Depending on the drug, a Loading Dose (LD) may be given to help achieve an immediate therapeutic response by reaching levels that are seen at steady state quickly. However, steady state is not reached any faster—3 to 5 half-lives are still needed.

C Dose adjustments are best made when the patient is at steady state
   a. Steady state is dependent only on half life (t ½)
   b. Pharmacokinetic parameters must remain stable for accurate dosing.
      (a) Renal function for renally eliminated drugs
      (b) Hepatic function for hepatically eliminated drugs
   c. Why is being at steady state important?
      (i) Minimizes potential for over/under dose adjustment
      (ii) Assumes maximum and stable distribution
   d. Level interpretation
      (i) The adjustment is only as good as the drug level assessment
      (ii) Was the level drawn appropriately in relation to the dose and from the appropriate IV line?
         (a) False levels may lead in inappropriate dose changes

D Dose adjustment may be needed when a patient is not at steady state
   a. Adjust based on the pharmacokinetic information available and the patient’s clinical condition.
   b. Frequent monitoring is essential.

E Dosing is not always “one stop shopping”
   a. Different doses may be needed to treat the same indication for different patients
   b. Patients with similar age, height, weight may still require different dosing

F Examples of drugs that require TDM
   a. Select antibiotics (Aminoglycosides, Vancomycin)
   b. Select antiepileptic agents (i.e. carbamazepime, phenytoin)
   c. Select anticoagulants (warfarin, heparin---monitor coagulation times not drug levels per se)

G Clinical Scenario
LC is a 41yo female who is being treated for E. Coli urosepsis. She has multiple true drug allergies and her only treatment option at this time is tobramycin.

Vital signs: stable
Height 64inches
Admission weight 60kg
Usual weight 57kg (IBW 55kg)
Bun 10 Cr 0.8
2+ pitting edema

You notice that she has not yet received any diuretic. You estimate her CrCl to be 78.3mL/min based on her admission weight and labs.
Your desired peak is 6mcg/mL and trough is <2mcg/mL.
Using population PK parameters of Vd of 0.25L/kg and a dosing interval of 8h you start the following:

Tobramycin 120mg x 1  
Then tobramycin 90mg Q8h starting 8hours after the first dose

Tobramycin levels are drawn at steady state (4th dose) along with other labs:  
Peak: 4mcg/mL (desired peak is 6mcg/mL)  
Trough: 0.5mcg/mL (desired trough is <2mcg/mL)  
Serum creatinine remains stable at 0.8mg/dL  
Weight 64kg  
3+ pitting edema

What is your assessment?

**Answer:** Aminoglycosides readily distribute into extracellular fluid. When dosing was initiated in this patient, she was dosed based on a euvolemic status or normal hydration state. However, she was fluid overloaded at the time of medication initiation and is even more fluid loaded at present. The tobramycin readily distributes into the extracellular fluid and in an edematous patient may result in lower serum levels if not dose adjusted. Slightly increasing the milligram amount of the dose would have accounted for some of the extracellular shifting. However, if the patient were to have been given a diuretic to help remove the extra water, the levels would have been right on target.

**IV. Drug Interactions**

A. Approximately 3-5% of inpatients are reported to have a preventable adverse drug reaction (ADE). (FDA)
B. Drug interactions are the leading cause of ER visits and hospital admissions. (FDA)
C. Drug interactions can occur before or after administration. (FDA)
D. Causes of drug interactions
   a. Drug incompatibility
   b. Pharmacokinetic interactions
      i. Absorption
      ii. Distribution
      iii. Metabolism
      iv. Elimination
   c. Pharmacodynamic interactions
E. Types of drug interactions
   a. Drug-Drug
   b. Drug- Nutrient
   c. Drug-Disease State
   d. Level of drug action or organ system
   e. Examples
i. Drug incompatibility
   1. At time of preparation or during administration set up
   2. Precipitation
      a. IV calcium and IV ceftriaxone (antibiotic)
   3. Amphotericin B (antifungal) and 0.9% sodium chloride

ii. Pharmacokinetic
   1. Absorption
      a. Will drug A affect absorption of drug B
      b. Chelation
         i. Levofloxacin (quinolone antibiotic) + ferrous sulfate
         ii. Ciprofloxacin (quinolone antibiotic) + yogurt
      c. Changes in stomach pH
         i. Itraconazole (antifungal) + cola soft drink
   2. Distribution
      a. Competition for binding sites
         i. Aspirin (NSAID) + warfarin (blood thinner)
      b. Changes in protein binding due to disease states
         i. Phenytoin (anti-seizure) + extensive burn patient
      c. Changes in extracellular fluid or adipose
         i. Vancomycin (antibiotic) + obese
   3. Metabolism
      a. Hepatic
         i. Inducer of CYP<sub>450</sub>
            1. Increased metabolism
               a. Carbamazepine (anti-seizure) + oral contraceptives
               b. Rifampin (antibiotic) + protease inhibitors (HIV medication)
         ii. Inhibitor of CYP<sub>450</sub>
            1. Decreased metabolism
               a. Simvastatin (cholesterol medication) + grapefruit juice
               b. Disulfiram + alcohol
               c. Disulfiram-like reaction
                  i. Metronidazole + alcohol
         iii. Major enzymes: 1A2, 2C9, 2C19, 2D6, 3A4
      b. Other metabolic pathways
         i. Plasma esterases
   4. Elimination
      a. Competition for elimination pathways
      b. Renal elimination is the most common
      c. Decreased or increased elimination
iii. Pharmacodynamic interactions
   1. Warfarin + spinach
      a. Warfarin inhibits vitamin K dependent clotting factors
      b. Spinach has vitamin K
      c. End result is decreased anticoagulant effect
   2. Dronedarone (antiarrhythmic) and NYHA class IV heart failure
      a. Dronedarone can worsen heart failure
   3. Medications that can prolong QTc interval
      a. Combination can increase risk of Torsades de Pointes
      b. E.g. amiodarone, haloperidol, levofloxacin, ondansetron
   4. Tobramycin (aminoglycoside antibiotic) + cyclosporine (immunosuppressant)
      a. Both drugs undergo renal elimination
      b. Both can cause nephrotoxicity
      c. Increased risk of nephrotoxicity if used in combination
   5. Methylprednisolone and glucose control
      a. Steroids can increase blood sugar

iv. Intentional vs. unintentional interaction
   1. Often, interactive properties of drugs may be used to enhance dosing regimen
      a. Amoxicillin + probenecid
         i. Probenecid decreased the renal elimination of amoxicillin
      b. Ritonavir + lopinavir (HIV protease inhibitors)
         i. Ritonavir is a CYP450 inhibitor
         ii. Increased lopinavir concentrations
         iii. Resulting in decreased dose
         iv. Decreased frequency of administration

v. Steps to minimize drug interactions
   1. Know your most commonly prescribed drugs
   2. Know your reputable references
   3. Education patients to use only one pharmacy and maintain accurate written medication histories
   4. Accurate and detailed medication reconciliation at each clinic visit, upon hospital admission, transfer and discharge
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Context</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>Calcium Channel Blocker</td>
<td>Drug Interaction</td>
<td>9</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>Beta lactam Antibiotic</td>
<td>Aminopenicillin</td>
<td>9</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Salicylate</td>
<td>Drug Interaction</td>
<td>8</td>
</tr>
<tr>
<td>Calcium Carbonate</td>
<td>Calcium Salt, antacid</td>
<td>Drug Interaction</td>
<td>8</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Antiepileptic agent</td>
<td>Drug Interaction</td>
<td>6,8</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>Beta lactam antibiotic</td>
<td>3rd generation cephalosporin</td>
<td>4,8</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Quinolone antibiotic</td>
<td>Drug Interaction</td>
<td>8, 10</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Immunosuppressant, IL II inhibitor</td>
<td>Drug Interaction</td>
<td>9</td>
</tr>
<tr>
<td>Didanosine</td>
<td>HIV, NRTI</td>
<td>Requires basic environment for absorption</td>
<td>2</td>
</tr>
<tr>
<td>Disulfiram</td>
<td>Aldehyde dehydrogenase inhibitor</td>
<td>Drug Interaction</td>
<td>8</td>
</tr>
<tr>
<td>Dronedarone</td>
<td>Antiarrhythmic</td>
<td>Drug interaction</td>
<td>8,9</td>
</tr>
<tr>
<td>Fentanyl Patches</td>
<td>Opioid analgesic</td>
<td>Absorption and skin temp</td>
<td>3</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Aminoglycoside antibiotic</td>
<td>Population PK example, Vd changes with increased ECF, TDM</td>
<td>5, 8</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>Atypical Antipsychotic</td>
<td>Drug Interaction</td>
<td>9</td>
</tr>
<tr>
<td>Heparin</td>
<td>Anticoagulant</td>
<td>TDM</td>
<td>6</td>
</tr>
<tr>
<td>Iron Sulfate</td>
<td>Mineral</td>
<td>Case</td>
<td>8</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Azole antifungal</td>
<td>Requires acidic environment for absorption, Drug Interaction</td>
<td>2, 8</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>Quinolone antibiotic</td>
<td>Drug interaction</td>
<td>8,9</td>
</tr>
<tr>
<td>Linezolid</td>
<td>Oxazolidanone antibiotic</td>
<td>Fecal elimination</td>
<td>4</td>
</tr>
<tr>
<td>Lopinavir/Ritonavir</td>
<td>HIV Protease Inhibitors</td>
<td>Drug Interaction</td>
<td>9</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>Corticosteroid</td>
<td>Drug Interaction</td>
<td>9</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Amebicide/antiprotozoal antibiotic</td>
<td>Drug Interaction</td>
<td>9</td>
</tr>
<tr>
<td>Oral Contraceptives (OCP)</td>
<td>Contraceptive</td>
<td>Drug Interaction</td>
<td>8</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Antiepileptic agent</td>
<td>Population PK example, Drug interaction</td>
<td>5, 6,8</td>
</tr>
<tr>
<td>Probenecid</td>
<td>Anti-gout</td>
<td>Drug interaction, Drug interaction</td>
<td>9</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>Drug interaction</td>
<td>Drug Interaction</td>
<td>8</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>Aminoglycoside antibiotic</td>
<td>TDM</td>
<td>6,7, 9</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Glycopeptide antibiotic</td>
<td>Drug reservoir (adipose) TDM</td>
<td>3, 6, 8</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Anticoagulant</td>
<td>TDM, Drug Interaction</td>
<td>6, 8, 9</td>
</tr>
</tbody>
</table>
Drug Metabolism

Date: Friday, August 5th, 2016 – 9:30 am

Relevant Reading:
*Basic and Clinical Pharmacology* - B.G. Katzung, 13th Edition, Chapter 4 p57-73

**KEY CONCEPTS & LEARNING OBJECTIVES**
At the end of the lecture the learner will be able to:

1. Describe the principal consequences of drug metabolism
2. List the major anatomical and subcellular locations involved in drug metabolism
3. Describe the first pass effect and how it contributes towards determining drug bioavailability
4. Describe the major features of Phase I and Phase II metabolic reactions and how they each contribute towards the modification of drug activity and drug elimination
5. List the major types of enzymatic reactions and enzymes involved in Phase I and Phase II metabolism
6. List the major CYP450 enzymes associated with drug metabolism and identify the enzyme isoforms that are principally responsible for metabolizing clinically used drugs
7. Describe the major features of CYP450 enzymes and the reactions they perform
8. Describe the principal differences between the metabolism of a typical drug and a prodrug
9. Describe how enterohepatic drug recirculation influences the elimination and pharmacokinetic parameters of drugs that are excreted in the bile
10. Describe the two principal mechanisms underlying metabolic drug-drug interactions and give specific examples of each.
11. Describe how grapefruit juice consumption can affect the metabolism of certain drugs
12. Identify well-known inhibitors and inducers of the CYP3A4 enzyme.
13. Describe the principal factors known to influence drug metabolism
The pharmacology of Drug Transporters

Date: Friday, August 5th, 2016 – 10:30 am

KEY CONCEPTS & LEARNING OBJECTIVES
At the end of the lecture the learner will be able to:

1. Describe the mechanisms by which drug transporter proteins contribute towards the transport of drugs across biological membranes
2. Describe the mechanisms by which drug transporter proteins can influence drug pharmacokinetics
3. Describe the mechanisms by which drug transporters can contribute towards drug-induced adverse effects
4. Describe the mechanisms by which drug transporters can contribute towards drug-drug interactions
5. Distinguish between the seven major families of drug transporter proteins based upon their mode of transport, patterns of expression and substrate specificity.
6. Describe the mechanism by which probenecid contributes towards interactions with drugs transported by the OAT class of drug transporters
7. Describe the role of the OATP1B1 transporter in influencing the pharmacokinetics of the STATIN class of drugs
8. Describe the mechanism by which cimetidine contributes towards interactions with drugs transported by the OCT class of drug transporters
9. Describe the role of the ATP-binding class of transporters in contributing towards the integrity of the Blood Brain Barrier
10. Describe the effects of cyclosporin, rifampicin and St. John’s Wort on the pharmacokinetics of drugs that are substrates for the P-glycoprotein/MDR1 drug transporter and discuss the underlying mechanisms
11. Describe the role of P-gp/MDR1 in determining the responsiveness of tumor cells to chemotherapeutic drugs
Pharmacogenetics/Pharmacogenomics

Date: Monday, August 8th, 2016 – 10:30 am

Relevant Reading:

KEY CONCEPTS & LEARNING OBJECTIVES
At the end of the lecture the learner will be able to:

1. Define pharmacogenetics and describe how it can be used to enhance patient care
2. List the main factors that can affect the genetic variability of the drug response
3. Describe how genetic polymorphisms in drug metabolizing enzymes can affect the metabolism of drugs and the effects that this has on serum drug concentration, drug efficacy and the risk of toxicity
4. Describe how polymorphisms in drug transporter proteins can contribute towards the variability in drug responses
5. Describe how polymorphisms in drug target proteins can contribute towards the variability in drug responses
6. Describe how polymorphisms in CYP2C9 and VKORC1 each contribute towards the variability in the response to warfarin
7. Discuss the different mechanisms by which genetic polymorphisms can contribute towards drug-induced adverse effects
8. List some of the current barriers to the full implementation of pharmacogenetics into clinical practice
9. Define targeted therapy and explain how pharmacogenetic data is used in the therapeutic decision making process
PHARMACODYNAMICS I: DRUG - RECEPTOR INTERACTIONS

Date: August 9, 2016 – 9:30 a.m.

KEY CONCEPTS AND LEARNING OBJECTIVES

1. Identify the principle characteristic that differentiates a biological receptor from a binding site.

2. Explain why increasing drug concentration (or dose) results in non-linear increases in receptor occupation and non-linear increases in response.

3. Identify the only two parameters that dictate receptor fractional occupancy for any drug and the equation that relates these two parameters to receptor fractional occupancy.

4. Compare the terms $K_D$ and its EC50 for an agonist and explain why the values of these terms would be identical in a system without spare receptors.

5. Explain why the clinical effectiveness of a drug is dependent on its maximal efficacy and not potency.

4. Construct and compare dose response curves for a full agonists, a partial agonists, a neutral antagonists and a negative antagonists (inverse agonists).

6. Explain why the response produced by any full agonist would not be increased by subsequent administration of a partial agonist acting on the same receptor.

7. Describe the different pharmacological and non-pharmacological mechanisms by which the effects of a drug can be antagonized.

8. Describe the concept of spare receptors (aka receptor reserve) and the effect increases in receptor reserve have on the shape of the graded dose -response curve.

9. Compare the effects of increasing concentrations of a non-competitive antagonist on an agonist dose response curve in system without spare receptors versus systems with spare receptors.

10. Compare the effects of increasing concentrations of a competitive antagonist on an agonist dose response curve in system without spare receptors versus systems with spare receptors.

11. Describe the fundamental difference between graded and a quantal dose response relationships and the specific information that each type of curve can provide.
PHARMACODYNAMICS I: DRUG-RECEPTOR INTERACTIONS

I. INTRODUCTION

Overview of Main Phases in Drug Action

<table>
<thead>
<tr>
<th>Pharmaceutical Phase</th>
<th>Pharmacokinetic Phase</th>
<th>PHARMACODYNAMIC PHASE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>drug available for absorption</td>
<td>absorption distribution metabolism excretion</td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical availability</td>
<td>drug available for action</td>
</tr>
<tr>
<td></td>
<td>Disintegration of dosage form &amp; dissolution of active substance</td>
<td>Drug-receptor interaction in target tissue</td>
</tr>
</tbody>
</table>

Adapted from: T.P. Kenakin, Analysis of Drug Receptor Interactions, 1987

A. **DRUG** - defined as any substance that affects living processes

- most, but not all, drugs produce their effects by interacting with specific receptors

- biologic responses to drugs are graded. Increasing the dose increases the effects

- their biologic effects, which can be therapeutic or toxic, depends on the drug, dose and "selectivity"

**Drug Nomenclature:** A drug is often referred to by a name that reflects its most prominent site of action or clinical effect, although it may interact with many other receptors within a given dose range. This “label” attached to a drug often determines how the drug is used or sometimes misused. Remember...

*Drug interactions with a receptor or receptors are dictated by the drug's chemical and structural properties, not by the name ascribed to it by humans.*

Chemical forces involved in drug binding include:

1. Electrostatic forces
2. Hydrogen Bonding
3. Van der Waals Forces (at closer distances)
4. Hydrophobic bonds
**Most Drug Receptor Interactions are REVERSIBLE**

Most Drug Binding Interactions DO NOT form Covalent Bonds

The reversible interaction (i.e. binding) of a drug with a receptor can be thought of as a dynamic equilibrium process. That is, the drug is either "on" or "off" the receptor at any point in time.

Implication: **ANY DRUG CAN INTERACT ONLY WITH UNOCCUPIED ("FREE") RECEPTORS**

- Drug “displacement” does not generally occur in drug-receptor interactions

**B. RECEPTORS versus “BINDING SITES”**

**RECEPTOR** - any component that is “receptive” to interacting with drugs or endogenous substances and is capable of initiating a subsequent response

**BINDING SITES** - “receptive” components that can interact with (or "bind" to) substances but are not capable of initiating any subsequent response are often referred to as "acceptor" sites or "binding" sites. (e.g. albumin and $\alpha_1$ acid glycoprotein).

**RECEPTOR SYSTEMS** - The receptor is only the first step in the transfer of drug "information" to the system. This is shown in the figure below.

**Diagram**

```
DRUG + RECEPTOR
(Discriminator)
```

**Main steps in the pharmacodynamic phase of action.**
II. RELATIONSHIP BETWEEN DRUG CONCENTRATION AND RECEPTOR OCCUPATION

The principles that apply to the binding of drugs to receptors are similar to those that govern chemical reactions and are analogous to the parameters observed in enzyme kinetics. Let’s see how:

Briefly: \[ D + R \rightleftharpoons DR \]
\[ D = \text{free drug} \]
\[ R = \text{free receptors} \]
\[ DR = \text{drug-receptor complex} \]

The rate of formation of DR complex with time is:

\[ \frac{d[DR]}{dt} = k_1 [D][R] \]

and the rate of breakdown of the DR complex with time is:

\[ -\frac{d[DR]}{dt} = k_2 [DR] \]

At equilibrium, these two rates are equal.

Therefore:

\[ k_1 [D][R] = k_2 [DR] \]
\[ \text{or } \frac{k_2}{k_1} = \frac{[D][R]}{[DR]} \]

The term \( \frac{k_2}{k_1} \) is the \( K_D \) (i.e., the equilibrium dissociation or affinity constant).

This \( K_D \) value of a drug for a given receptor reflects the propensity of a drug to bind to that receptor. This propensity to interact with a receptor (i.e., form [DR]) is referred to as the drug's affinity for the receptor and it is typically expressed by the \( K_D \) value for a given receptor. Consequently, if a drug has a high affinity for a receptor, [DR] will be large. From the above equation, if [DR] is large, the value of \( K_D \) will be small.

Thus, for any drug, the \( K_D \) value and affinity are inversely related.

Also, the \( K_D \) value for any drug is the concentration of that drug that will occupy 50% of a receptor population (see eqn below).

You (yes, I mean YOU) can determine the fraction of any receptor population that will be occupied by any concentration of any drug by using the simple Receptor Fractional Occupancy Equation (shown below)

\[ \text{Fractional Occ.} = \frac{1}{1 + \frac{K_D}{[D]}} \]
Thus, for any drug, the FRACTION of a receptor population that it will occupy will depend ONLY on it’s: (1) **affinity** and (2) **concentration** (i.e. dose).

- Note that the fraction of receptors occupied by any drug will be independent of the number of receptors present in a tissue.
- However, the total number of receptors occupied by a drug will depend on both: (1) fraction of the receptor population occupied & (2) the number of receptors in a given tissue, (i.e., $B_{\text{max}}$)

The magnitude of the RESPONSE will be some function (i.e. $\alpha$) of the total number of receptors occupied.

$$\text{Response} = \alpha \text{ (fractional occupancy) (Receptor \#)}$$

**Relationship between Drug Dose (concentration) and Receptor Occupancy:** Increasing dose will increase receptor occupation in a non-linear fashion over most of the dose range (fig. below).

As the concentration of a drug increases, the fraction of receptors occupied by the drug will increase from 1 - 91% over approximately 3 orders of magnitude (3 log units of drug concentration) about its $K_D$ value, as shown in the figure below.

In the figure below, drug concentration is expressed as a function of its affinity (i.e. $K_D$ units of concentration) so that the receptor occupation curve shown applies to any drug.

For example: if the $K_D$ for a drug is 5nM, then a 5nM concentration of the drug could be expressed as 1$K_D$ unit of concentration, 10nM would be 2$K_D$ units, etc.
Drug Selectivity: Since most drugs have comparable affinity for a number of receptors, the selectivity of a drug refers to its ability to interact with one type of receptor versus other receptors. For any drug, selectivity will decrease as dose is increased. This is shown in the figure below:

Adapted from: T.P. Kenakin, Pharmacological Analysis of Drug Receptor Interactions, 1987

The “selectivity window” of a drug is dependent on the drug dose or concentration range employed. It can be difficult to obtain this range in vivo where numerous other factors are operative (e.g. drug distribution, metabolism, tissue receptor heterogeneity, etc.).

III. GRADED DOSE RESPONSE CURVES – The Relationship Between Drug DOSE, Receptor Occupation and the magnitude of the RESPONSE

The Dose-Response Relationship: This is the correspondence between the amount of a drug and the magnitude of the effect produced. The initial step in producing any effect is the binding (i.e. interaction) of a drug with a receptor.

\[ D + R \rightarrow DR \rightarrow \text{RESPONSE} \]

Simple Occupancy Theory – predicts that there is a one to one relationship between receptor occupation and response. Thus:

1) the magnitude of the pharmacological effect is linearly proportional to the number of receptors occupied by the drug

2) the maximum response is obtained only when all receptors are occupied.
Modified Occupancy Theory - Expansion of simple occupancy theory to account for experimental findings that could not be explained by the original theory. Thus:

1. The response of a drug was some positive function of receptor occupancy (i.e., not necessarily linearly proportional to the percent of receptors occupied).
2. Maximum effects could be produced by an agonist occupying only a small proportion of receptors.
3. Different drugs may have varying capacities to initiate a response.

These findings resulted in the concepts of Drug Efficacy and Potency

Efficacy (a.k.a. maximal efficacy, intrinsic activity) - this can be determined directly from the graded dose-response curve and is the limit (or plateau) of the dose-response curve on the response axis

Thus: Full agonists would have an intrinsic activity = 1 Partial agonists would have an intrinsic activity < 1 and Neutral Antagonists that bind but produce no biologic effect would have an intrinsic activity of 0. Negative Antagonists (Inverse Agonists) reduce the response produced by constitutively active receptors (active in the absence of agonist) and have a negative intrinsic activity.

Potency - refers to the concentration or dose of a drug necessary to produce 50% of that drug’s maximal response and is expressed as an ED₅₀ value. The potency of a drug depends in part on: (1) its affinity for the receptor (i.e., its Kᵦ value), and (2) the efficiency with which drug-receptor interaction is coupled to response.

THE CLINICAL EFFECTIVENESS OF A DRUG DEPENDS ON ITS MAXIMAL EFFICACY (Emax) NOT ON ITS POTENCY (ED₅₀).

Adapted from: R.A. Lehne, Pharmacology for Nursing Care, 1990

Comparison of drugs differing in efficacy and potency

1. A is more potent than B and C.
2. A and B have equal efficacies.
3. B and C are equipotent but B is more efficacious than C.
4. A is more potent and more efficacious than C.

Adapted from: R.A. Lehne, Pharmacology for Nursing Care, 1990.
Spare Receptors (Receptor Reserve)

In most systems, a maximum response can be obtained using doses of agonists that occupied only a small percentage or fraction of receptors. Such a system is referred to as having “receptor reserve” or containing “spare receptors”.

Shape of Graded Dose Response Curve – sometimes provides information about spare receptors. If it takes 3 log units of concentration (dose) for a drug to occupy 91% of any receptor population yet a maximal response occurs over a more narrow dose range (e.g. < 3 log units), not all receptors need to be occupied to produce that maximal response (i.e. there are “spare receptors”).

Note the difference in range of concentrations for the same agonist, noradrenaline, to produce an Emax response in Tissue 1 (> 3 log units) versus Tissue 2 (~1.5 log units). This large difference in DR range indicates large differences in receptor reserve (or spare receptors) for the same receptor in tissue 1 versus tissue 2. Smaller differences in receptor reserve may not be revealed by such obvious visual differences in the DR curves. (figure provided by GB)

Experimentally, spare receptors can be demonstrated using increasing concentrations of a non-competitive (irreversible) antagonist to eliminate an increasing number of the available receptors. Curve A is the effect of the agonist alone. Curves B - E show the effect of the same agonist in the same system with fewer and fewer receptors.

Modified from B.G. Katzung, ed. Basic and Clinical Pharmacology p14, 2004
ANTAGONISM OF DRUG EFFECTS

1. Pharmacological Antagonism

   A. Competitive Antagonists: (Surmountable Antagonism)

Since an antagonist will "bind" but not elicit a response, higher concentration of agonist are required to occupy the same number of receptors to produce an equivalent response to that observed at lower concentrations in the absence of antagonist. Competitive antagonists will change the ED$_{50}$ of the agonist for the receptor rather than reduce the maximal response (Emax).

![Graphs showing response vs. dose for agonist alone, agonist plus low dose antagonist, agonist plus high dose antagonist, and antagonist alone.]

Modified from: R.A. Lehne, Pharmacology for Nursing Care, 1990

B. Non-Competitive Antagonists: (Insurmountable Antagonism)

Non-competitive antagonists bind to the receptor and result in a change in the receptor that effectively removes it from the sites available to interact with the drug (this process could be reversible or irreversible). Consequently, if there is no receptor reserve, there would be a decrease in the maximal response (Emax) due to the loss of available receptors to be activated. However, the remaining receptors would exhibit the same affinity (K$_D$) for the drug and thus the ED$_{50}$ would not be altered.

![Graphs showing response vs. dose for agonist alone, agonist plus low dose antagonist, agonist plus high dose antagonist, and antagonist alone.]

Modified from: R.A. Lehne, Pharmacology for Nursing Care, 1990
C.  **Antagonism by Partial Agonists**

Since partial agonists can bind to the full complement of a receptor population but cannot produce the maximal response of full agonists, they can reduce the maximal response of full agonists when both drugs are administered together.

![Graph](image1)

**From: B.G. Katzung, ed., Basic and Clinical Pharmacology p 19, 2009**

Other Types of Non-Pharmacological Antagonism

- **Chemical antagonists** - chemical inactivation of a drug
  e.g., protamine (positively charged) inactivation of heparin (negatively charged)

- **Physiologic antagonism** - the use of opposing regulatory pathways to antagonize the effects of a drug. These effects are less specific and less easy to control than the effects of a receptor specific antagonist.
IV. **THE QUANTAL DOSE RESPONSE CURVE** -the Relationship between Drug DOSE & a SPECIFIED EFFECT produced in a Patient or Animal Population

Obtained from the cumulative frequency distribution of doses of drug required to produce a specified (i.e. quantal) effect in a large number of patients or experimental animals.

Can be used to obtain the median effective dose ($ED_{50}$). This is the dose at which 50% of individuals will exhibit a specified effect.

Can be used to obtain an index of the selectivity of a drug's actions by comparing its $ED_{50}$ for different specified effects.

Can be used to determine the **therapeutic index**, representing some estimate of the safety of a drug. It is the ratio of the $TD_{50}$ or $LD_{50}$ to the $ED_{50}$ determined from quantal dose response curves.

This is illustrated in the figures below:

![Quantal Dose Response Curve Diagram](image)


**Therapeutic window** – the dosage range between the minimum effective therapeutic dose (or conc.) and the minimum toxic dose (or conc.). This is a more clinically relevant index of safety.
PHARMACODYNAMICS II: DRUG-RECEPTOR INTERACTIONS

Date: August 10, 2016 – 8:30 a.m.

KEY CONCEPTS AND LEARNING OBJECTIVES (what you should be able to do)

1. Describe the concepts of drug stereospecificity and saturability.
2. Describe the ways that receptor function can be altered by physiological, pharmacological and pathological factors.
3. Describe the factors that can affect the magnitude of response that can be produced by an agonist.
4. Describe the key aspects of the 5 major types of receptor signaling mechanisms, the conceptual similarities and differences and how they differ in response times.
5. Describe the ternary complex model of G-protein activation and signaling of subsequent messengers.
6. Describe the steps involved in receptor signaling via the adenylyl cyclase and Phospholipase C pathways and their respective downstream effectors.
7. Describe the different means by which drugs can produce beneficial versus toxic effects and the different strategies that may be used to maximize the beneficial effects.
8. Describe the different types of variations in responsiveness to drugs.
9. Compare homologous and heterologous desensitization in terms of: (a) respective mechanisms, (b) its effect on the agonist dose response curves and (c) the therapeutic consequences of the altered responsiveness to drugs.
10. Describe the phenomenon of receptor supersensitivity, the factors that can produce it, how it affects the dose response curve and the therapeutic consequence of supersensitivity.
I. RECEPTORS - IMPORTANT GENERAL FEATURES

1. **Structural Specificity**: Receptors exhibit some degree of specificity for the drug molecule. The component of the receptor that "recognizes" and "binds" the drug is known as the receptor recognition site or pharmacophore.

2. **Stereospecificity**: Receptors generally exhibit stereospecificity for drugs containing asymmetric carbon atoms.

![A pair of optical enantiomers showing the different patterns of projection of three functional groups onto a receptor surface](image)


3. **Saturability**: Receptors exist in finite numbers and as such can be saturated by high concentrations (i.e. doses) of drug. Therefore, increasing the dose after saturating (occupying) all receptors will not increase its response any further.

4. **Response**: There will be some quantitative relationship between the magnitude the pharmacological response and the number of receptors occupied.

The response to a drug depends on:

1. the amount of drug reaching its site of action (pharmacokinetic consideration)
2. the drug-receptor interaction at that site
3. the functional status of the receptor and/or target cell

5. **Regulation**: Receptors are dynamic entities that can be affected by physiological, pharmacological and pathological factors. (e.g. pharmacodynamic tolerance, supersensitivity, etc.)
II. TYPES OF DRUG RECEPTORS AND SIGNALING MECHANISMS


A INTRACELLULAR RECEPTORS

These receptors are not bound to a membrane. They exist in the cytosol and can bind biologic compounds that are sufficiently lipid soluble to cross the plasma membrane.

The binding of the compound may:

(1) stimulate an intracellular enzyme (e.g. soluble guanylyl cyclase) or

(2) regulate cellular localization of the receptor and alter transcription of genes (e.g. the glucocorticoid receptor).

The latter receptors are considered "GENE ACTIVE" receptors since they bind to promoters to stimulate the transcription of genes in the nucleus.

Therapeutic Consequences of Gene Active Receptors

1. There is a lag period of 30 minutes to a few hours, the time required for new protein synthesis.

2. The effects of these agents can persist for hours or days after the agonist is no longer present.

Implication: The therapeutic or toxic effects of gene-active agents will decrease slowly. There is no simple temporal correlation between plasma hormone concentrations and effects.
B. **PLASMA-MEMBRANE BOUND RECEPTORS**

1. **Ligand-Regulated Transmembrane Enzymes Including Protein Tyrosine Kinase**

Receptor polypeptides that cross the plasma membrane & consist of an extracellular hormone binding domain and a cytoplasmic enzyme domain. The enzymatic domain may be **tyrosine** or **serine kinase** or **guanylyl cyclase**. Drug binding initiates an allosteric activation of the cytoplasmic enzyme domain. Once activated, these receptors can phosphorylate downstream substrate proteins.

The autophosphorylation of tyrosine residues on the receptor's cytoplasmic domain can intensify or prolong the duration of activation of the receptor.

These types of receptors are subject to receptor down-regulation via endocytosis of receptors from the cell surface followed by degradation of the receptors and their bound ligand.

Examples of endogenous substances that utilize tyrosine kinase receptors are: insulin, epidermal growth factor (EDF), and platelet-derived growth factor (PDGF).

*From: B.G. Katzung, ed. Basic and Clinical Pharmacology, page 22, 2009*
Cytokine Receptor Mechanism

- closely resembles receptor tyrosine kinase but utilizes a separate protein tyrosine kinase that binds non-covalently to the membrane.

*Figure 2-11. Cytokine receptors, like receptor tyrosine kinases, have extracellular and intracellular domains and form dimers. However, after activation by an appropriate ligand, intracellular protein tyrosine kinase molecules (JAKs) are activated, resulting in phosphorylation of STAT molecules. STAT dimers then travel to the nucleus, where they regulate transcription.*

From Katzung, pg 24, 2009

2. **Ligand Gated Channel Receptors** - These receptors transmit their signals by increasing the flow of relevant ions and altering the electrical potential across the membrane. Examples of transmitters utilizing this mechanism include: (1) acetylcholine, (2) GABA and (3) the excitatory amino acids (e.g. glutamate, aspartate).

The **Nicotinic Cholinergic Receptor** (a prototypic channel receptor) - a pentamer composed of four types of glycoprotein subunits in the molar ratio $\alpha_2\beta\delta\gamma$. The homologous subunits form a cylindrical structure that contains a cation channel whose opening is regulated by acetylcholine binding. The $\alpha$-subunits contain the binding sites for acetylcholine.

Acetylcholine binding produces a conformational change that results in the transient opening of a channel through which sodium ions can pass from the extracellular fluid into the cell.

Time between binding and response can be measured in milliseconds.

The rapidity of this signaling mechanism provides rapid information transfer across the synapse.

*From: B.G. Katzung, ed. Basic and Clinical Pharmacology, page 24, 2009*
3. **G-Protein Family of Transmembrane Receptors:**

Receptors coupled to guanine nucleotide regulatory proteins (G-proteins), comprise a structurally related family. The single polypeptide chain of these receptors traverse the plasma membrane 7 times. The *amino terminus* in the extracellular space and the *carboxy terminus* in the cytoplasm. The extracellular region contains the ligand or drug recognition site while the third intracellular loop of these receptors regulates the ability of the receptor to interact with specific G-proteins.

![Diagram of G-Protein Coupled Receptors](image)

*From*: B.G. Katzung, ed *Basic and Clinical Pharmacology*, page 26, 2009

**Guanine Nucleotide Regulatory Proteins (G-Proteins)** - proteins that act as *intermediates* in the transfer of information between the receptor and the second messenger. They are composed of alpha, beta and gamma subunits that exist together as a trimer. Different G proteins mediate the stimulatory and inhibitory effects on adenyl cyclase and the activation of phospholipase C. These G proteins are referred to as Gs, Gi and Gq and differ primarily in their alpha subunits ($\alpha_s$ and $\alpha_i$ and $\alpha_q$, respectively).

**Activation of G-Protein Coupled Receptors:**

a) Agonist binds to receptor and facilitates its association with a G-protein (i.e. formation of a ternary complex)

b) Formation of the **Ternary Complex** facilitates the binding of GTP rather than GDP to the G-protein.

c) Binding of GTP to the alpha subunit dissociates it from the beta-gamma subunits, receptor and agonist.

d) The GTP-bound G-protein is the active intermediate which changes the activity of the effector component, usually an ion channel or enzyme such as adenyl cyclase or phospholipase.

e) The G-protein remains active until a GTPase converts GTP to GDP reforming the original non-reactive G-protein.
The separation of receptor activation from G-protein mediated activation of the effector facilitates amplification of the transduced signal.

Two Well Established G-protein Signaling Pathways

Adenylyl Cyclase

Phosphoinositide Hydrolysis

Modified from B.G. Katzung, ed., Basic and Clinical Pharmacology, page 28, 2009

Note that reversible phosphorylation is a common theme in these signaling mechanisms that provides for amplification (activation of multiple substrates) and flexible regulation (e.g., via cellular availability of particular kinases or kinase substrates).
Beneficial Versus Toxic Effects of Drugs

Because no drug causes only a single specific effect, drugs are classified according to their **principal** action.

Since drugs are **selective** rather than specific in their actions, their selectivity can be considered with respect to two categories: **therapeutic** versus **toxic** effects.

The term "**side effect**" is often used to identify some toxic or unwanted effect of a drug.

Beneficial versus toxic effects of drugs may result via 3 different means.

1. **Actions at the same receptor** - direct pharmacologic extension of the therapeutic actions of the drug (e.g. excessive bleeding caused by anticoagulant therapy).
   - Toxicity may be minimized or prevented by careful management of dose and monitoring of effect, or by not administering the drug at all.

2. **Actions at identical receptors but in different tissues or affecting different effector pathways** - e.g. Glucocorticoid congeners used to treat asthma or inflammatory disorders can produce protein catabolism, psychosis, etc. (all mediated by similar or identical glucocorticoid receptors)

   - 3 strategies to avoid or mitigate these effects:
     a) Administer the lowest dose that produces an acceptable benefit
     b) Administer adjunctive drugs - may allow lowering the dose of the first drug
     c) Limit the drug’s effects to specific parts of the body (e.g. aerosol administration of a glucocorticoid to the bronchi)
3. **Actions Mediated by Different Types of Receptors** - minimize toxic or side effects by prescribing drugs with greater receptor selectivity (e.g. selective serotonin uptake blockers rather than tricyclic antidepressants)

These 3 possible relationships between beneficial versus toxic effects of a drug are shown below.


### III. VARIATION IN DRUG RESPONSIVENESS

**Idiosyncratic drug response** - an unusual response that is not frequently observed in the majority of patients.

**Quantitative Variations in drug response** - more common and more clinically important

- the intensity of effect for a given dose of a drug may be increased (*hyperreactive*) or diminished (*hyporeactive*) in comparison with the effect observed in most individuals.

- The intensity of response to a drug dose may change during the course of therapy.
  - response may be decreased (desensitization) or increased (supersensitivity)

**Reduced Responsivness Upon Drug Exposure**

**Tachyphylaxis** - a term used to describe the rapid development of diminished responsiveness after administration of a drug.
**Pharmacodynamic tolerance** (Desensitization Phenomenon) - a decreased responsiveness to pharmacologic or hormonal stimulation that occurs slowly with time.

These are general mechanisms of cellular adaptation that can markedly limit the therapeutic effectiveness of a number of drugs.

Familiar examples include:
- the loss of bronchodilating effects of β-adrenergic agonists in asthmatics;
- the decreased vasoconstricting response to α-adrenergic agonists used as decongestants.

**Effect on Dose-Response Curve**: Agonist dose-response curves will be shifted to the right ($\uparrow$ ED50) and Emax may be reduced if receptor reserve is exceeded.

Some mechanisms mediating reduced responsiveness include:

1) Agonist-induced phosphorylation of the activated receptor and binding of β-arrestin (readily reversible).

2) Receptor Down-Regulation - there is a loss of membrane bound receptors responsible for eliciting the response.

3) Post-Receptor Adaptations – receptors also may become functionally "uncoupled" from post receptor moieties due to functional modification of G-proteins and/or subsequent second messenger enzymes.

**Homologous Desensitization of β-Adrenergic Receptors**

β-adrenergic receptors are phosphorylated via β-adrenergic receptor kinases (aka GRK2, GRK3) that functionally uncouple the receptors and can trigger their sequestration from the cell. There is a loss of activity only to agonists interacting with the modified receptor.

*From Katzung. Basic and Clinical Pharmacology, page 21, 2009*
HOMOLOGOUS DESENSITIZATION (only the activated receptor affected)


**Effect on Agonist Dose-Response Curve:** Desensitization will result in a shift to the right in the dose response curve for agonists since higher fractional occupancy is required to achieve responses comparable what was achieved at lower occupancy in non-desensitized systems. **Typically,** the same Emax can still be achieved, due to large receptor reserve. However, Emax may be reduced in some types of desensitization (e.g. where receptor loss exceeds system reserve or downstream post receptor defects reduce maximal responding).

**Heterologous Desensitization:** agonist activation of a single receptor subtype results in a decreased responsiveness of one or more other receptor subtypes (i.e. receptors that were not directly activated by the drug). Thus, drugs that produce heterologous desensitization will have more widespread effects in a system. This may be due to modification of receptors other than the specific type that was directly activated by the drug.

Several protein kinases seem to be capable of promoting phosphorylation of the receptors including: cAMP dependent protein kinase (PKA) and protein kinase C (PKC).

Receptor function is regulated by phosphorylation in the absence of receptor sequestration or down regulation. This modification serves to functionally uncouple these receptors and impair their interactions with guanine nucleotide regulatory proteins.
In addition, heterologous desensitization may be associated with functional modifications at post-receptor intermediate(s) in the effector pathway (e.g. guanine nucleotide regulatory proteins).

**HETEROLOGOUS DESENSITIZATION (multiple receptors and signaling affected)**

![Diagram showing heterologous desensitization](image)


**Increased Responsiveness to Drugs**

**Supersensitivity** (aka “denervation supersensitivity”)

- a compensatory receptor mechanism in which the loss of hormonal activity on receptors leads to an *increase* in the number of receptors and/or an enhanced receptor-effector coupling.

Thus, in a supersensitive system, any given dose or concentration of drug will produce a greater response than in the control situation.

**Effect on the Dose-Response Curve:** This results in a shift to the *left (←)* and a decrease in the ED50 of the agonist dose-response curve.
Drug Toxicity

Date: Wednesday, August 10th, 2016 – 9:30 am

KEY CONCEPTS & LEARNING OBJECTIVES
At the end of the lecture the learner will be able to:

1. Define a drug-induced adverse effect
2. List some of the factors that can influence the development of a drug-induced adverse effect
3. Explain how drug toxicity can result from the effects of a drug on its direct molecular target
4. Explain how drug toxicity can result from “off-target” effects
5. Explain how the metabolism of harmful metabolites can contribute towards drug toxicity
6. Describe the mechanisms by which an overdose of acetaminophen can cause hepatotoxicity
7. Describe why timely treatment with N-acetylcysteine can be effective in the treatment of acetaminophen poisoning.
8. Describe how drugs can trigger the immune system to cause adverse effects
9. Define idiosyncratic toxicity, the influence of genetics in developing an idiosyncratic drug reaction, and the potential mechanisms involved
10. Define the term teratogen
11. Describe the classification of drugs used in pregnancy and identify categories of drugs that can and cannot be used in the treatment of women who are pregnant
#12 - DRUG DISCOVERY & CLINICAL TRIALS

**Date:**  Wednesday, August 10th, 2015 – 10:30 am

**KEY CONCEPTS & LEARNING OBJECTIVES**

*At the end of the lecture the learner will be able to:*

1. Describe the principal three stages of drug discovery and development and their specific roles in the drug development process

2. Describe the essential elements of compound-centered and target-centered drug discovery

3. Define the role of lead drug optimization in the context of the drug development process

4. Describe the principal goal of pre-clinical drug development, the major steps involved in this process and their primary function.

5. Describe the process by which a new drug candidate becomes an approved new drug.

6. Describe the functions of the Food and Drug Administration (FDA) in the drug approval process

7. Describe the composition, primary functions and role of Institutional Review boards in the drug approval process

8. Describe the primary purpose of an Investigational New Drug Application (IND) and list the major required components of the application.

9. Describe the three distinct types of Investigational New Drug Application (IND) and their specific uses.

10. Describe the basic elements and primary purpose of the four stages of clinical trial, including the typical number of participants, the setting, typical trial design, endpoints and primary objective

11. Define the purpose and contents of a New Drug Application (NDA)

12. List the FDA-approved data that must be included on the approved drug packaging label

13. Define the three classes of drug recall

14. Describe the process by which generic drugs are approved including what critical pharmacological information needs to be provided to support the application